Identification of MKP-1 as a central mediator of cytoprotective effects in human endothelial cells: pathways of induction by Fürst, Robert
 
 
Dissertation zur Erlangung des Doktorgrades 
der Fakultät für Chemie und Pharmazie 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
Identification of MKP-1 as a central mediator of 
cytoprotective effects in human endothelial cells: 
pathways of induction 
 
 
 
 
 
Robert Fürst 
aus Temeschburg 
2005 

 
 
 
Erklärung
Diese Dissertation wurde im Sinne von § 13 Abs. 3 bzw. 4 der Promotionsordnung vom 29. Januar 
1998 von Frau PD Dr. Alexandra K. Kiemer und Frau Prof. Dr. Angelika M. Vollmar betreut. 
 
 
 
Ehrenwörtliche Versicherung
Diese Dissertation wurde selbstständig, ohne unerlaubte Hilfe erarbeitet. 
 
 
 
München, 03.12.2004 
 
         ____________________ 
                  (Robert Fürst) 
 
 
 
 
 
 
 
 
Dissertation eingereicht am:  03.12.2004 
1. Gutachter:   Frau Prof. Dr. Angelika M. Vollmar 
2. Gutachter:   Herr Prof. Dr. Ernst Wagner 
Mündliche Prüfung am:  03.02.2005 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deeply grateful and with love 
dedicated to my family 
 
Contents  I 
 
 
 
 
Contents 
 
II  Contents   
 
Contents  III 
1 INTRODUCTION   1 
1.1 The endothelium  3 
1.1.1 Endothelial cell characteristics  3 
1.1.2 Atherosclerosis, inflammation, and endothelial cell activation  4 
1.2 Aim of the study  6 
1.3 MAP kinases and MAP kinase phosphatases  7 
1.4 Atrial natriuretic peptide  10 
1.5 ROS and NAD(P)H oxidase  13 
1.6 Glucocorticoids  15 
 
2 MATERIALS AND METHODS  19 
2.1 Materials  21 
2.2 Cell culture  22 
2.2.1 Solutions  22 
2.2.2 Culture of HUVEC and HMEC  22 
2.2.3 Passaging  23 
2.2.4 Long time storage  23 
2.2.5 Starvation  23 
2.3 Western blot analysis  24 
2.3.1 Solutions  24 
2.3.2 In vivo samples  25 
2.3.3 In vitro samples  25 
2.3.4 Stripping, reprobing, and coomassie staining  26 
2.4 RT-PCR  26 
2.4.1 Isolation and characterization of total RNA  26 
2.4.2 Reverse transcription  27 
2.4.3 Polymerase chain reaction  27 
 
IV  Contents   
 
2.5 ROS measurement in cultured endothelial cells  28 
2.6 ROS measurement in the endothelium of intact rat lung vessels  31 
2.6.1 Animals  31 
2.6.2 Isolated-perfused rat lung preparation  31 
2.6.3 In situ fluorescence microscopy  32 
2.7 Electrophoretic mobility shift assay (EMSA)  33 
2.7.1 Extraction of nuclear protein  33 
2.7.2 Radioactive labeling of consensus oligonucleotides  33 
2.7.3 Binding reaction and electrophoretic separation  34 
2.8 Transfection experiments  35 
2.8.1 Rac1 mutants  35 
2.8.2 Antisense oligodesoxynucleotides  35 
2.8.3 AP-1 decoy  36 
2.9 Rac pull-down assay  36 
2.9.1 Principle of the assay  36 
2.9.2 Preparation of the GST-PBD sepharose beads  37 
2.9.3 Pull-down assay  38 
2.10 Immunocytochemistry and confocal microscopy  39 
2.11 Flow cytometry (FACS)  39 
2.12 Statistical analysis  40 
 
3 RESULTS 41 
3.1 ANP and MKP-1  43 
3.1.1 MKP-1 induction by ANP  43 
3.1.1.1 Time and concentration course of MKP-1 induction 43 
3.1.1.2 Influence of cycloheximide on MKP-1 induction  44 
3.1.1.3 MKP-1 induction depends on cGMP/NPR-A  44 
3.1.1.4 PKG I is not expressed in HUVEC  45 
 
Contents  V 
3.1.2 ANP induces endothelial ROS production  45 
3.1.2.1 Time and concentration course of ROS generation  45 
3.1.2.2 ROS generation depends on cGMP/NPR-A  46 
3.1.3 ROS mediate the induction of MKP-1 by ANP  47 
3.1.3.1 Antioxidants abrogate ANP-induced MKP-1 expression  47 
3.1.3.2 Hydrogen peroxide induces MKP-1  47 
3.1.4 Involvement of NAD(P)H oxidase  48 
3.1.4.1 Influence of PEG-SOD and SOD on ANP-induced ROS generation  48 
3.1.4.2 Influence of PEG-catalase and catalase on ANP-induced ROS generation  49 
3.1.4.3 Influence of DPI and gp91ds-tat on ANP-induced ROS generation  49 
3.1.4.4 Influence of PEG-SOD and SOD on ANP-induced MKP-1 expression  50 
3.1.4.5 Influence of PEG-catalase and catalase on ANP-induced MKP-1 expression  51 
3.1.4.6 Influence of DPI and apocynin on ANP-induced MKP-1 expression  51 
3.1.4.7 Expression of Nox homologues’ transcripts in HUVEC and HMEC  52 
3.1.4.8 Influence of Nox2 and Nox4 antisense on ANP-induced ROS generation  52 
3.1.4.9 Influence of Nox2 and Nox4 antisense on ANP-induced MKP-1 expression  53 
3.1.5 Involvement of Rac1  53 
3.1.5.1 ANP activates Rac1   53 
3.1.5.2 ANP induces Rac1 translocation  54 
3.1.5.3 Rac1 is crucially involved in ANP-induced ROS generation 
  and MKP-1 expression  55 
3.1.6 MKP-1 induction is not mediated by PKC, ERK, or p38 MAPK  55 
3.1.7 Role of JNK and AP-1  56 
3.1.7.1 JNK mediates the induction of MKP-1 by ANP  56 
3.1.7.2 ANP rapidly activates JNK  57 
3.1.7.3 Superoxide is involved in the activation of JNK by ANP  57 
3.1.7.4 ANP activates AP-1 via JNK  58 
3.1.7.5 AP-1 is crucially involved in the upregulation of MKP-1 by ANP  58 
3.1.8 ROS generation in intact blood vessels  59 
VI  Contents   
 
3.2 Dexamethasone and MKP-1  62 
3.2.1 Dex reduces TNF-α-induced E-selectin expression  62 
3.2.2 Dex at low concentrations does not influence NF-κB  62 
3.2.3 p38 MAPK is involved in TNF-α-induced E-selectin expression  63 
3.2.4 Influence of Dex on TNF-α-activated p38 MAPK  64 
3.2.5 Vanadate abrogates the influence of Dex on p38 MAPK  65 
3.2.6 MKP-1 induction by Dex  65 
3.2.7 Dex induces MKP-1 via glucocorticoid receptor  66 
3.2.8 MKP-1 antisense restores p38 MAPK activation  66 
3.2.9 MKP-1 antisense restores E-selectin expression  67 
 
4 DISCUSSION  69 
4.1 ANP and MKP-1  71 
4.1.1 Beneficial actions of MKP-1  71 
4.1.2 ANP induces MKP-1  72 
4.1.3 Generation of ROS by ANP  73 
4.1.4 Involvement of NAD(P)H oxidase  74 
4.1.5 The role of Rac1  76 
4.1.6 Involvement of the JNK/AP-1 pathway  77 
4.1.7 General comments  78 
4.2 Dexamethasone and MKP-1  79 
4.2.1 Dex reduces E-selectin expression independent of NF-κB  79 
4.2.2 The role of p38 MAPK in TNF-α-induced E-selectin expression  79 
4.2.3 Dex reduces p38 MAPK activity via induction of MKP-1  80 
4.2.4 MKP-1 is critical for the inhibition of p38 MAPK activity and E-selectin induction  81 
4.2.5 The functional role of MKP-1 induction by Dex  81 
 
 
 
Contents  VII 
5 SUMMARY  83 
5.1 MKP-1 and ANP  85 
5.2 MKP-1 and Dex  85 
5.3 MKP-1 as a central protective mediator of the endothelium  86 
 
6 REFERENCES  89 
 
7 APPENDIX  107 
7.1 Abbreviations  109 
7.2 Alphabetical list of companies  111 
7.3 Publications  113 
7.3.1 Original publications  113 
7.3.2 Reviews  113 
7.3.3 Oral presentations  114 
7.3.4 Poster presentations  115 
7.3.5 Awards  115 
7.4 Curriculum vitae  116 
7.5 Acknowledgements  117 
VIII  Contents   
 
 
Introduction 1 
1 Introduction 
2 Introduction 
Introduction 3 
1.1 The endothelium 
1.1.1 Endothelial cell characteristics 
The endothelium is a monolayer of cells which line the lumen of all blood vessels, thereby serving as a 
barrier between blood and tissue. In the past, the endothelium has been described as a non-reactive, 
inert vessel “wall paper”. During the last decades, it became clear that endothelial cells (ECs) actively 
participate in many physiological processes. The endothelium is now regarded as a disseminated 
organ with important metabolic, synthetic, secretory, and immunological functions, exerting influence 
on smooth muscle cells, platelets, and leukocytes via autocrine and paracrine mechanisms.1 
 
(i) The endothelium has important transport functions: ECs tightly control the passage of molecules 
and cells from the blood to the underlying interstitium by different mechanisms, such as active 
transport (e.g. for glucose, amino acids), transcytosis (e.g. by caveolae), or paracellular transport (e.g. 
through tight junctions). These mechanisms are of great importance in order to meet the metabolic 
needs of the underlying tissue.1,2 
 
(ii) The endothelium controls the vascular tone and is important for blood pressure regulation. ECs 
produce many substances which act as vasodilators or vasoconstrictors. These substances are 
released in response to humoral and mechanical stimuli and affect the adjacent smooth muscle cells. 
Prominent vasodilators are nitric oxide (NO) and prostacyclin (PGI2). Endothelin-1 (ET-1) and the 
platelet-activating factor (PAF) represent important vasoconstricting factors.1,2 
 
(iii) The endothelium regulates coagulation. On their surface, ECs express a variety of molecules that 
regulate hemostasis. Resting ECs provide an anti-thrombotic surface by expressing anti-thrombotic 
factors (e.g. glycosaminoglycans, thrombomodulin) and by secreting anti-thrombotic autacoids (NO, 
PGI2, adenosine), thus facilitating blood flow and inhibiting platelet adhesion and coagulation. Vascular 
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injury induces tissue factor (TF) expression and the endothelium gets transformed to a pro-coagulant 
state.1,2 
 
(iv) The endothelium plays a key role in the body’s host defense and in inflammation: ECs are 
strategically well positioned at the tissue-blood barrier. In general, the immune response depends on 
the communication between cells by different mediators, such as cytokines. ECs are able to produce 
and react to a variety of these mediator substances, thereby interfering with inflammatory 
processes.1,2 An initiating step in inflammatory events is the recruitment of circulating leukocytes 
towards sites of inflammation. These leukocytes have to transmigrate across the endothelium 
(diapedesis), a process which is tightly controlled by ECs. Moreover, ECs are able to directly react to 
infections: different cytokines, adhesion molecules, and enzymes (such as matrix metalloproteinases 
or NO synthase) are upregulated in the endothelium in response to a variety of microbial mediators.3,4 
 
In the recent years, not only the important physiological functions of ECs have been investigated. The 
endothelium has also increasingly been recognized to be involved in different pathophysiological 
states: a disturbed endothelial function plays a crucial role in a variety of diseases, such as 
atherosclerosis, sepsis, hypertension, diabetes, thrombotic disorders, and cancer metastasis.2 Thus, 
influencing different endothelial processes by affecting the underlying molecular signaling mechanisms 
has become an important approach for drug discovery in order to defeat these severe disorders. 
1.1.2 Atherosclerosis, inflammation, and endothelial cell activation 
Atherosclerosis is the most important contributor to cardiovascular disease (CVD). CVD currently 
represents the major reason for premature deaths in industrial countries.5 Therefore, understanding 
and influencing the pathogenesis of atherosclerosis is of utmost importance in order to discover new 
approaches for drug therapy. Atherosclerosis is a chronic disorder, which is characterized by the 
formation of plaques in arterial blood vessels. These atheromatous plaques can occlude the vessel 
leading to a damage of the surrounding tissue due to a strongly impaired oxygen supply. From a 
classical view, the major cause for atherosclerosis is the accumulation of fatty deposits (oxidized 
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lipoproteins) and fibrous elements in the vessel lumen. In the past, scientists focused their research on 
the involvement of lipoproteins and smooth muscle cell proliferation. In recent years, however, 
atherosclerosis has increasingly been recognized as a predominantly inflammatory disease.5-7 In 
addition to the involvement of inflammatory cells (T-lymphocytes, monocytes/macrophages), many 
pro-inflammatory mediators (cytokines, mainly interleukins and tumor necrosis factor-α [TNF-α]) 
initiate different responses that promote atherosclerosis.8 These substances switch ECs from a resting 
to an activated status, which is characterized by an induction of adhesion molecules, increased 
oxidative stress, and reduced nitric oxide generation.3,4,9 
risk factors
(oxidized lipoproteins,
infectious agents, etc.)
pro-inflammatory cytokines
(interleukins, TNF-α)
activated endothelial cell
NF-κB↑
CAM leukocyte
leukocyte
leukocyte adherence
 
Figure 1: The attachment of circulating leukocytes to activated endothelial cells is widely regulated by cellular 
adhesion molecules (CAMs) and the transcription factor nuclear factor-κB (NF-κB). 
 
An increased recruitment and attachment of circulating leukocytes to the endothelium was found to be 
an early step in the development of atherosclerosis.7,10,11 The adherence of leukocytes to ECs 
(figure 1) and their subsequent migration across the endothelium (diapedesis) depends on a cascade 
of events mediated by a family of cell adhesion molecules (CAMs) expressed on the endothelial 
surface. Vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), 
and E-selectin represent important CAMs, which are involved in the pathogenesis of atherosclerosis.6 
Interleukins and TNF-α are known to strongly induce CAM expression. The induction of CAMs seems 
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to be largely regulated by the transcription factor nuclear factor-κB (NF-κB, figure 1), a central 
mediator of the innate immune response, which controls a great variety of inflammatory events.12,13 
1.2 Aim of the study 
In recent years, MKP-1, the mitogen-activated protein kinase phosphatase-1, has increasingly been 
recognized as an important mediator responsible for the transduction of anti-inflammatory and 
cytoprotective effects in different cell-types. MKP-1 predominantly acts as a negative regulator of 
different members of the family of mitogen-activated protein kinases (MAPKs), which take part in the 
control of diverse cellular functions. Thus, MKP-1 is able to affect important physiological and 
pathophysiological events. Interestingly, the role of MKP-1 in the endothelium has as yet been only 
poorly investigated. 
 
Aim of the present study was to characterize the role of MKP-1 in endothelial cells. A precise definition 
of both the functions of MKP-1 and the mechanisms of its induction is of special interest considering 
this phosphatase to be a valuable drug target. For this purpose, two different projects were pursued: 
 
(i) Characterization of the pathway by which ANP induces MKP-1 expression: 
In the model of endothelial inflammation, i.e. in TNF-α-activated endothelial cells, the cardiovascular 
hormone atrial natriuretic peptide (ANP) was shown to exert significant protective, anti-inflammatory 
actions: ANP reduces stress fiber formation, macromolecular permeability, and the attraction of 
leukocytes.14,15 Since the ANP-induced induction of MKP-1 is critical for all of these effects, we wanted 
to elucidate the underlying molecular signaling mechanisms leading to an upregulation of MKP-1 by 
ANP, thereby focusing on an involvement of protein kinases and reactive oxygen species (ROS). 
 
(ii) Characterization of the function of glucocorticoid-induced MKP-1 expression: 
MKP-1 has been introduced as a potential mediator of the anti-inflammatory effects of glucocorticoids 
in different cell types. However, nothing has as yet been known about the role of MKP-1 in the 
signaling of glucocorticoids in endothelial cells. We aimed to clarify whether MKP-1 is upregulated in 
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endothelial cells by the synthetic glucocorticoid dexamethasone (Dex). Moreover, we also wanted to 
reveal the functional significance of MKP-1 induction: in a model of endothelial inflammation (ECs 
activated by TNF-α), we aimed to elucidate the effect of MKP-1 on the expression of the CAM 
E-selectin. Since E-selectin is largely regulated by NF-κB, a discrimination between MKP-1 and NF-κB 
as targets of the anti-inflammatory actions of Dex was required. 
1.3 MAP kinases and MAP kinase phosphatases 
Cells must permanently be responsive to biochemical and biophysical signals. Most stimuli to which 
cells react are sensed by receptors on the cytoplasma membrane. These receptors generate signals 
which have to be transmitted to the respective cellular target by intracellular signal transduction 
pathways. The phosphorylation and dephosphorylation of proteins – exerted by the enzyme families of 
protein kinases and phosphatases, respectively – is the most important step by which a signal is 
intracellularly relayed. A major group of signal transducers in eukaryotes is the family of mitogen-
activated protein kinases (MAPKs). MAPKs not only relay, but also amplify and integrate diverse 
signals in order to coordinate the cellular response. They participate in a huge variety of physiological 
and pathological processes.16,17 
initiating events
MKKK
MKK
MAPK
biological response
stimulus
cell membrane
 
Figure 2: MAPK signaling pathway. Upon an extracellular stimulus, a kinase cascade is initiated leading to distinct 
biological responses, like an altered gene expression or an activation of further kinases. Abbreviations: 
MAPK kinase kinase (MKKK), MAPK kinase (MKK). Adapted from Herlaar et al.18 
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MAPKs belong to different signaling cascades composed of different protein kinases in series, termed 
MAPK kinase kinase (MKKK) and MAPK kinase (MKK), that lead to a final activation of an effector 
MAPK, which is in turn able to influence multiple cellular targets. Mostly, MAPKs alter gene expression 
or activate further kinases.18 
 
Three major MAPK families are known: (i) extracellular-regulated protein kinases (ERK), (ii) c-Jun N-
terminal kinases (JNK), and (iii) p38 MAPKs. Each MAPK family comprises of different isoforms. The 
ERK pathway plays a prominent role in processes like cell proliferation and differentiation. JNK and 
p38 MAPK are predominantly involved in apoptosis, stress response, and in inflammatory events.19-21 
All MAPKs are activated by the same biochemical way (figure 2): MKKK phosphorylates the dual 
specificity serine/threonine kinase MKK, which phosphorylates both the threonine (Thr) and tyrosine 
(Tyr) residue in the activation loop of MAPK. Both residues have to be phosphorylated for activation of 
the MAP kinases. All MAPKs share the sequence Thr-X-Tyr. X differs depending on the MAPK family: 
glutamic acid for ERK, proline for JNK, and glycine for p38 MAPK.18,19 
 
The mechanisms of MAPK activation have been extensively studied in the last decades. The 
pathways of their deactivation, however, have as yet been investigated to a much lesser extent, 
although MAPK inactivation has increasingly been recognized as a crucial event in the cellular signal 
transduction network. The dephosphorylation of one critical amino acid (Thr or Tyr) is sufficient to 
inactivate MAPKs. Three types of phosphatases can be involved in the process of MAPK deactivation: 
protein tyrosine phosphatases (PTPs) and serine/threonine-specific phosphatases, which remove one 
phosphate, or dual-specificity phosphatases (DUSPs), which remove both phosphates (figure 3).22,23 
 
M
A
PK
Thr
Xxx
Tyr
P
P
DUSPs/MKPs
PTPs
serine/threonine
phosphatases
 
Figure 3: Inactivation of MAPKs. Three classes of phosphatases are able to inactivate MAPKs: serine/threonine 
phosphatases, protein tyrosine phosphatases (PTPs), and dual-specificity phosphatases (DUSPs)/MAPK 
phosphatases (MKPs). 
Introduction 9 
DUSPs are regarded as key players for the inactivation of different MAPK families and have therefore 
also been termed MAPK phosphatases (MKPs). Ten genes coding for members of the MKP family are 
known so far. Due to structural similarities, MKPs can be divided into three subgroups. MKP-1 
(DUSP1, hVH1, CL100, 3CH134) and MKP-2 (DUSP4, hVH2, TYP1) are two important members of 
the subgroup I. They both show a nuclear localization (for MKP-1 see figure 4). MKP-3 (DUSP6, rVH6, 
PYST1) is the prototypical member of subgroup II, which shows a cytosolic localization. Subgroup III 
consists of MKP-7 (DUSP16, MKP-M, localized in the cytosol) and vVH5 (DUSP8, M3/6, localized in 
the nucleus and the cytosol, shuttle protein).24 
 
 
Figure 4: MKP-1 is localized in the nucleus. Human umbilical vein endothelial cells (HUVECs) were stained for MKP-1 
and confocal microscopy was performed as described in section 2.10. 
 
 
exon 1 exon 2 exon 3 exon 4
catalytic site
docking domain
Cdc25 homology (CH2) domains  
Figure 5: Structure of subgroup I MKPs (e.g. MKP-1). Adapted from Theodosiou et al.24 
 
The structure of subgroup I of MKPs is schematically depicted in figure 5. The catalytical site of MKPs 
is known to exist in a low-activity state. Upon binding of the substrate (activated MAPKs), the critical 
active-site residues are rearranged and adopt a catalytically active conformation. MKPs contain two 
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regions with similarity to the Cdc25 phosphatase and one docking site for MAPKs, which is able to 
bind to the common docking domain (CD) of MAPKs.24 
 
MKP-1 is able to bind all three major types of MAPKs, i.e. ERK, JNK, and p38 MAPK.23 Binding of 
MAPKs was shown to result in phosphorylation of MKP-1, which does not influence its catalytical 
activity, but seems to stabilize MKP-1 by reducing its catabolism.24 MKP-1 is known to be rapidly 
degraded (half live approx. 45 min) by the ubiquitin/proteasome-pathway.25 MKP-1 is constitutively 
expressed at low levels and underlies – as an immediate early gene product26 – a tight and rapid 
transcriptional upregulation by different stimuli, predominantly by agents which induce MAPKs, which 
means that MKP-1 takes part in a negative feedback loop controlling the activity of MAPKs.22  
 
As mentioned in chapter 1.2, we aimed to elucidate the underlying signaling mechanisms leading to 
an upregulation of MKP-1 in human endothelial cells by the cardiovascular hormone atrial natriuretic 
peptide. Interestingly, only little is known about the signaling events leading to an induction of MKP-1 
in endothelial cells. Based on the knowledge of an involvement of reactive oxygen species (ROS)27,28 
and different kinases (MAPKs, protein kinase C),29-32 we hypothesized that ROS initiate a signaling 
cascade leading to an activation of kinases, which results in an increased expression of MKP-1. 
1.4 Atrial natriuretic peptide 
In 1981 de Bold et al. observed that an infusion of atrial tissue extracts into rats causes a strong 
natriuresis.33 This study was the initial point for the discovery of the natriuretic peptide (NP) family, a 
family of cardiovascular hormones. The first discovered member, atrial natriuretic peptide (ANP), was 
described as a natriuretic, diuretic, and vasorelaxant agent. Later on, two other NPs were discovered: 
brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP).34 Recently, dendroaspis 
natriuretic peptide (DNP), originally found in the green mamba snake, was revealed to be present in 
humans.35 
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ANP is primarily produced in the cardiac atria. The most important stimulus for its release is an 
increased atrial wall tension. ANP is a circular, disulfide bond-containing peptide composed of 28 
amino acids (figure 6), which is generated by cleavage of the precursor hormone pro-ANP.36 
 
 
Figure 6: Structure of human atrial natriuretic peptide (ANP). 
 
BNP was initially discovered in brain homogenates, but the predominant sites of its synthesis and 
release are ventricular myocardial cells. Both ANP and BNP exert natriuretic, diuretic, and 
vasorelaxant effects and play an important role as regulators of blood pressure and volume 
homeostasis by counterbalancing the renin-angiotensin-aldosterone system. Target organs 
predominantly represent the kidneys for ANP and BNP, and the vasculature for CNP, which is mainly 
expressed in the brain and seems to be an important neuroendocrine regulator. Moreover, relevant 
amounts of CNP are produced by the endothelium and CNP is suggested as an autocrine/paracrine 
vasoregulator.34,37 
 
Natriuretic peptides exert their various effects by binding to three different types of transmembrane NP 
receptors (NPRs).38-40 Their structure is schematically depicted in figure 7. NPR-A and NPR-B are 
particulate guanylyl cyclases. Most of the biological actions of NPs are mediated by these receptors. 
Their activation results in an increase of intracellular cyclic guanosine monophosphate (cGMP) levels. 
NPR-A predominantly binds ANP and BNP, whereas NPR-B shows the strongest affinity to CNP. The 
third receptor, NPR-C, binds all NPs and mainly acts as a clearance receptor and plays an important 
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role in the elimination of NPs. Besides this action, NPR-C has also been shown to mediate an 
inhibition of adenylyl cyclase and an activation of phospholipase C via inhibitory G proteins.41 
 
extracellular
domain
kinase homology
domain
guanylyl cylase
GTP GTPcGMP
ANP
NPR-A NPR-B NPR-C
BNP CNP ANP BNP CNP
clearance
 
Figure 7: Structure of the natriuretic peptide receptors (NPRs). 
 
NPs not only affect the body’s volume homeostasis, but also seem to play a fundamental role in 
cardiovascular remodeling and have functions as diagnostic parameters for cardiovascular 
conditions.42 ANP and BNP have also proven a therapeutic potency: for a few years they have been 
available as drugs for the treatment of acutely decompensated heart failure. Besides the 
administration of exogenous NP, increasing endogenous NP levels by inhibition of their degradation is 
suggested as a potentially valuable therapeutic strategy for cardiovascular disease.43 
 
Besides its prominent role in regulating volume homeostasis and cardiac function, ANP has been 
shown to be vasoprotective: ANP exerts proliferative effects on the endothelium and has, therefore, 
beneficial actions in vascular regeneration. ANP also possesses the potency to maintain endothelial 
barrier function, i.e. ANP can protect against endothelial hyper-permeability. Moreover, ANP was 
shown to largely inhibit the attraction and adhesion of leukocytes and to induce cytoprotective 
proteins, such as heme oxygenase-1.37 
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1.5 ROS and NAD(P)H oxidase 
In the 1950s, the appearance of free radicals in biological materials was discovered.44 Two major 
types of free radicals exist: reactive oxygen species (ROS) with superoxide as most relevant member, 
and reactive nitrogen species (RNS) with nitric oxide (NO) as major representative (figure 8). The 
superoxide anion is formed by the univalent reduction of oxygen. This process is mediated by 
enzymes such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox), xanthine 
oxidase, or by components of the mitochondrial electron transport chain. As a highly reactive radical, 
superoxide is rapidly converted into the nonradical hydrogen peroxide (H2O2), a process which is 
catalyzed by the enzyme superoxide dismutase (SOD). In the presence of transition metals, such as 
ferrous ions, superoxide can be converted into the highly reactive hydroxyl radical. The relatively 
stable oxidant hydrogen peroxide is mainly degraded by the enzymes catalase and glutathione 
peroxidase (GPx). NO is generated enzymatically by NO synthase (NOS) and is able to rapidly react 
with superoxide, leading to the formation of peroxynitrite.45,46 
 
O2
- •O2
e-
H2O2 H2O
OH•ONOO-
SOD catalase
GPx
NO Fe2+•
 
Figure 8: Pathways of reactive oxygen species (ROS) formation and degradation. 
 
For several decades, ROS were considered as toxic by-products of metabolic processes being able to 
badly damage cellular components. Many pathological states have been linked to elevated ROS levels 
(oxidative stress), such as cancer, atherosclerosis, hypertension, diabetes mellitus, rheumatoid 
arthritis, chronic heart failure, and ischemia reperfusion injury.45,47 In the last years, more and more 
studies revealed that radicals not only take part in pathophysiological processes, but also participate in 
cell signaling and regulation of cell functions, and therefore can be regarded as second messenger 
molecules.48-50 Numerous physiological actions are regulated by ROS, mainly involving the controlled 
production of NO by NOS or superoxide by Nox. Prominent examples are the regulation of vascular 
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tone, cell adhesion, immune response, and programmed cell death.45,47 A particularly active field of 
research deals with the role of ROS in the cardiovascular system. ROS seem to have distinct 
functions on each cell type in the vasculature, especially on vascular smooth muscle and endothelial 
cells. Both are able to produce ROS mainly by the NAD(P)H oxidase enzyme family.47,51 
gp91phox
p22phox
p47phox PO4
p67phoxp40phox
Rac
e-
Fe
Fe
FAD
NADPH
O2O2•
-
cytoplasma
 
Figure 9: Structure of the phagocyte NAD(P)H oxidase (phox) in its active form. Abbreviations: flavin adenine 
dinucleotide (FAD), nicotinamide adenine dinucleotide phosphate (NADPH). 
 
NAD(P)H oxidase was discovered in phagocytic leukocytes, such as neutrophils, eosinophils, and 
monocytes/macrophages, which play a highly important role in the innate immune response. A crucial 
component of this response is the ability of phagocytes to generate high amounts of ROS via Nox. 
The prototypical phagocyte-type NAD(P)H is a multi-component, flavin-heme enzyme which transfers 
electrons across the plasma membrane to oxygen (figure 9). The univalent reduction of molecular 
oxygen results in the formation of a superoxide anion. Superoxide is released into the extracellular 
milieu as well as into phagocytic vacuoles. The phagocyte Nox is composed of membrane-bound and 
soluble cytosolic subunits. The membrane-bound cytochrome b558 complex consists of the two 
subunits gp91phox and p22phox. The cytosolic components are p47phox, p67phox, p40phox and the small 
Rho-GTPase Rac1/2. p47phox, p67phox, and p40phox exist as a cytosolic macromolecular complex. Upon 
different stimuli (e.g. phagocytosis), NAD(P)H oxidase assembles in a complex process involving 
phosphorylation of p47phox, Rac activation, and cytoskeleton-dependent translocation of the cytosolic 
components to the plasma membrane. Only the fully assembled complex expresses catalytic 
activity.52-54 Recent evidence shows that all NAD(P)H oxidase subunits are present and functional in 
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human endothelial cells. In contrast to phagocyte Nox, the oxidase is constitutively active at a very low 
level even in resting cells.55 Accordingly, endothelial Nox was suggested to exist preassembled in 
association with membranes of the endoplasmatic reticulum.56-61 
 
With the increase of information concerning the human genome, several novel gp91phox homologues 
have been discovered, suggesting that enzymes similar to the phagocytic oxidase function in a variety 
of tissues. The physiological functions of these novel NAD(P)H oxidases (Nox1, Nox2 ≡ gp91phox, 
Nox3, Nox4, and Nox5) are widely unknown and currently under intensive investigation. In endothelial 
cells, besides Nox2/gp91phox, Nox4 has been found as a catalytically active Nox homologue.62 
 
Concerning the involvement of the small Rho-GTPase Rac, it is known that both isoforms, Rac1 and 
Rac2, are able to activate Nox53. The family of Rho-GTPases consists of Rho, Rac, and Cdc42. The 
Rho family is part of the Ras superfamily of GTP-binding proteins. GTPases act as a molecular switch, 
cycling between an active GTP-bound and an inactive GDP-bound state. In the active state, Rho- 
GTPases are able to interact with a variety of target molecules to initiate a downstream response, 
while the intrinsic GTPase activity returns the proteins to the inactive GDP-bound state.63 Besides its 
crucial role as an activating subunit of NAD(P)H oxidases in phagocytes, Rac is also of great 
importance for cytoskeletal reorganization processes.64,65 
1.6 Glucocorticoids 
In 1950, Hench, Kendall, and Reichstein won the Nobel Prize in Medicine and Physiology for the 
discovery of the adrenal cortex hormones, their structures, and biological effects.66 Glucocorticoids 
(GCs), predominantly cortisol (hydrocortisone), are produced by the cortex of adrenal glands using 
cholesterol as starting substance. Their production is regulated by the adrenocorticotropic hormone 
(ACTH) from the anterior pituitary. ACTH, in turn, is controlled by the corticotropin-releasing hormone 
(CRH) from the hypothalamus. GCs are essential for normal development and exert influence on 
different metabolic processes. Their name derives from the effect of raising blood glucose levels due 
to stress situations by stimulating gluconeogenesis in the liver, which involves catabolic processes like 
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proteolysis and lipolysis. Moreover, GCs affect the immune system by exerting anti-inflammatory 
actions: GC inhibit the release of proteolytic enzymes, leukocyte diapedesis, the arachidonic acid 
cascade, histamine release, and synthesis of different pro-inflammatory cytokines.67 
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Figure 10: Structure of the synthetic glucocorticoid dexamethasone (Dex). 
 
Synthetic glucocorticoids, such as dexamethasone (Dex) (figure 10), are well established and widely 
used immunosuppressive, anti-inflammatory drugs. GCs have been proven to exert beneficial effects 
in different autoimmune diseases and in a plethora of disorders with an inflammatory component, e.g. 
chronic allergic diseases, asthma, rheumatoid arthritis, Crohn’s disease, or chronic ulcerative colitis.67 
 
Principally, GC act by binding to their intracellular glucocorticoid receptor (GR). Subsequently to its 
ligand-dependent activation, the receptor translocates to the nucleus and acts (i) as a transcription 
factor upon binding to glucocorticoid responsive elements (GRE) of distinct gene promoters or (ii) as a 
direct inhibitor of transcription factors like signal transducers and activators of transcription (STATs), 
activator protein-1 (AP-1), or NF-κB68 – a protein-protein interaction known as transrepression (figure 
11). Metabolic effects, which represent most side effects of GCs, are mainly ascribed to the 
transcriptional activity of GR, whereas the anti-inflammatory actions are thought to be predominantly 
mediated via the mechanism of transrepression.69,70 The development of “dissociative glucocorticoids” 
which solely activate transrepression without affecting metabolic processes is thought to solve the 
problem of deleterious side effects in the long-term treatment with GC.71 
 
Since some of the GC actions, like acute anti-anaphylactic or cardiovascular protective effects, are 
known to be very rapid, a new concept of “non-transcriptional” GR effects emerged in the last years: 
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the activated GR initiates a signaling cascade without a direct action on gene transcription (figure 11). 
However, an indirect, subsequent downstream transcriptional activation mediated by the initiated 
signaling pathway is not excluded.72 
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Figure 11: Transcriptional and non-transcriptional effects of glucocorticoids (GC). GC readily cross the cytoplasma 
membrane and activate the cytosolic glucocorticoid receptor (GR), which either exerts direct effects on 
signaling cascades (such as MAPKs) or translocates to the nucleus and regulates gene transcription via 
acting as a transcription factor or via the mechanism of transrepression. 
 
In the context of non-transcriptional GR effects, a crosstalk between GC and MAPK pathways has 
increasingly been investigated.73 GC have been shown to induce MKP-1 in different cell-types.74 The 
induction seems to be mediated via GR and to depend on ongoing transcription. An involvement of 
MKP-1 in the anti-inflammatory effects of GCs in the endothelium has as yet not been investigated. 
Therefore, we aimed to clarify whether Dex is able to induce MKP-1 in endothelial cells. We also 
wanted to reveal a functional relevance of the Dex-induced increase of MKP-1 protein: in a model of 
endothelial inflammation, i.e. in TNF-α-activated endothelial cells, we investigated the involvement of 
MKP-1 in Dex-induced reduction of p38 MAPK activity and E-selectin expression. As mentioned in 
chapter 1.1.2, E-selectin is known to be largely regulated by NF-κB, a discrimination between p38 
MAPK and NF-κB as targets of the anti-inflammatory actions of Dex was mandatory. 
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2.1 Materials 
Medium 199, glutamine, penicillin, streptomycin, and amphotericin B were from PAN Biotech 
(Aidenbach, Germany). Fetal bovine serum (FBS) was from Biochrom (Berlin, Germany). DMEM was 
from Cambrex (Verviers, Belgum). Endothelial cell growth medium (ECGM) was from Promocell 
(Heidelberg, Germany). Atrial natriuretic factor (1-28, rat) (ANP) was from Calbiochem (Schwalbach, 
Germany) or from Bachem (Heidelberg, Germany), and cANF from Saxon Biochemicals (Hannover, 
Germany). 8-Br-cGMP, SB203580, calphostin C, PD98059, phorbol-12-myristate-13-acetate (PMA), 
and SP600125 were from Calbiochem (Schwalbach, Germany). Endothelial medium supplement, 
tumor necrosis factor-α (TNF-α), dexamethasone (Dex), cycloheximide, tiron, diphenyleneiodonium 
chloride (DPI), N-acetyl-L-cysteine (NAC), ebselen, superoxide dismutase (SOD), pegylated 
superoxide dismutase (PEG-SOD), catalase, pegylated catalase (PEG-catalase), isopropyl-β-D-
thiogalactopyranoside (IPTG), and apocynin were from Sigma-Aldrich (Taufkirchen, Germany). NG-
nitro-L-arginine (L-NNA) was from Alexis (Grünberg, Germany). Complete®, collagenase A, and 
GTPγS were from Roche (Mannheim, Germany). N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) 
was from USB (Cleveland, USA). LB broth base (Lennox LB broth base) was from Gibco/Invitrogen 
(Karlsruhe, Germany). Anti-gp91phox/Nox2, anti-p47phox, anti-Nox4, and anti-MKP-1 antibody were from 
Santa Cruz (Heidelberg, Germany). Anti-JNK and anti-phospho-JNK were from Cell Signaling/New 
England Biolabs (Frankfurt am Main, Germany), and anti-Rac from Upstate/Biomol (Hamburg, 
Germany). AlexaFluor488 goat anti-mouse, dihydrofluorescein diacetate (H2FDA), and 
dihydrodichlorofluorescein diacetate (H2DCFDA) were from Molecular Probes/Invitrogen (Karlsruhe, 
Germany). Phycoerythrin (PE)-labeled anti-E-selectin (CD62E) was from Leinco/Biotrend (Cologne, 
Germany). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit was from Dianova (Hamburg, 
Germany) and HRP-conjugated goat anti-mouse from Biozol (Eching, Germany) or Cell Signaling/New 
England Biolabs (Frankfurt am Main, Germany). AP-1 decoy and scrambled decoy, i.e. 
phosphorothioate-modified oligodesoxynucleotides, and primers for MKP-1 and Nox1-5 were from 
MWG Biotech (Ebersberg, Germany). MKP-1, gp91phox/Nox2, and Nox4 sense and antisense 
oligodesoxynucleotides were from biomers.net (Ulm, Germany). All other chemical agents (analytical 
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grade) were from Sigma-Aldrich (Taufkirchen, Germany), from Roth (Karlsruhe, Germany), or from 
Merck (Darmstadt, Germany). 
2.2 Cell culture 
2.2.1 Solutions 
Phosphate buffered saline (PBS) pH 7.4 is composed of NaCl 123.2 mM, KH2PO4 3.16 mM, and 
Na2HPO4 10.4 mM. Phosphate buffered saline pH 7.4 with magnesium and calcium (PBS+) consists 
of NaCl 137 mM, KCl 2.68 mM, Na2HPO4 8.10 mM, KH2PO4 1.47 mM, MgCl2 0.5 mM, and CaCl2 0.68 
mM. 
2.2.2 Culture of HUVEC and HMEC 
Human umbilical vein endothelial cells (HUVEC) were prepared by digestion of umbilical veins with 0.1 
g/l collagenase A (37°C, 45 min).75 For experiments investigating the induction of MKP-1 by ANP, 
HUVEC were cultured in Medium 199 supplemented with 20 % heat-inactivated fetal bovine serum 
(FBS), 2 % endothelial medium supplement, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2.5 µg/ml amphotericin B. For experiments regarding the investigation of the 
induction of MKP-1 by dexamethasone, HUVEC were cultured in endothelial cell growth medium 
supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin.  
 
CDC/EU.HMEC-1 (human microvascular endothelial cells, HMEC) were obtained from the CDC 
(Atlanta, USA). HMEC are an immortalized cell line (human dermal microvascular endothelial cells 
transfected with a plasmid coding for the transforming SV40 large T-antigen) that has been shown to 
retain endothelial morphologic, phenotypic, and functional characteristics.76 HMEC were cultured in 
endothelial cell growth medium supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. 
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The cells were cultured in an incubator (Heraeus, Hanau, Germany) in a humidified atmosphere at 
5 % CO2 and 37°C. Both HUVEC and HMEC were routinely tested for mycoplasma contamination with 
the PCR detection kit VenorGeM (Minerva Biolabs, Berlin, Germany). 
2.2.3 Passaging 
For passaging, cells were washed twice with PBS and detached by treating with a trypsin/ethylene 
diamine tetraacetic acid (EDTA) (T/E) solution containing trypsin 0.05 % and EDTA 0.02 % in PBS for 
1-2 min at 37°C. The digestion was stopped with Medium 199 containing 10 % heat-inactivated FBS, 
100 U/ml penicillin, 100 µg/ml streptomycin, and 2.5 µg/ml amphotericin B. Generally, cells were 
subcultured to a ratio of 1:3 (related to area) in cell culture flasks or plates (TPP, Trasadingen, 
Switzerland) and grown until confluence. HUVEC of passage no. 3 were used for all experiments. 
2.2.4 Long-time storage 
For long-time storage confluent cells were trypsinized, centrifuged, and resuspended in freezing 
medium, which consists of cell culture medium supplemented with 10 % dimethylsulfoxide (DMSO, 
cryoprotectant). The cell suspension was transferred to cryovials and gradually frozen at -20°C for one 
day, at -80°C for one week, and then stored at -196°C in liquid nitrogen. For thawing, cells were 
rapidly warmed to 37°C, centrifuged, and resuspended in cell culture medium. 
2.2.5 Starvation 
In general, cells were starved for 4 h in pure Medium 199 before performing experiments. For 
experiments performed with dexamethasone, cells were additionally starved overnight in a 
glucocorticoid-free starvation medium (DMEM containing 20 % heat-inactivated charcoal-stripped 
FBS, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin B, and 
10 ng/ml basic fibroblast growth factor). Since fetal bovine serum (FBS) contains significant amounts 
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of different steroids, such as glucocorticoids, cells are permanently exposed to glucocorticoids during 
cell growth. To eliminate an influence of the medium on the glucocorticoid system, steroids were 
removed by charcoal-treatment: FBS was gently swirled with activated charcoal overnight at 4°C and 
afterwards cleaned from charcoal by repeated centrifugation. 
2.3 Western blot analysis 
2.3.1 Solutions 
Cell lysis buffer contained tris(hydroxymethyl)aminomethane-HCl (Tris-HCl) pH 7.4 50 mM, sodium 
dodecyl sulfate (SDS) 0.1 %, nonidet P-40 (NP-40/Igepal CA 630) 1 %, sodium deoxycholate 0.25 %, 
NaCl 150 mM, Complete® (protease inhibitor cocktail) 4 %, phenylmethylsulfonyl fluoride (PMSF, 
protease inhibitor) 1 mM. For the protection of phosphorylated proteins the buffer additionally 
contained the phosphatase inhibitors NaF 1 mM and activated Na3VO4 1 mM. 3x Laemmli sample 
buffer was composed of Tris-HCl pH 8.8 187.5 mM, SDS 6 %, glycerol 30 %, β-mercaptoethanol 12.5 
%, and bromphenolblue 0.015 %. The resolving gel (10 %) contained an acrylamide 30 %-
bisacrylamide 0.8 %-solution (rotiphorese® Gel 30) 40 %, Tris pH 8.8 375 mM, SDS 0.1 %, N,N,N’,N’-
tetramethylethylenediamine (TEMED) 0.1 %, and ammonium peroxodisulfate (APS) 0.5 %. The 
stacking gel contained rotiphorese® Gel 30 17 %, Tris pH 6.8 125 mM, SDS 0.1 %, TEMED 0.2 %, and 
APS 1 %. The electrophoresis buffer consisted of Tris 0.3 %, glycine 1.44 %, and SDS 0.1 %. The 
anode buffer contained Tris 12 mM, N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) 8 mM, and 
methanol 15 %, and the cathode buffer Tris 12 mM, CAPS 8 mM, and SDS 0.1 %. Tris-buffered saline 
solution with tween (TBS-T) pH 8.0 is composed of Tris 0.3 %, NaCl 1.1 %, and tween 20 0.2 %. 
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2.3.2 In vivo samples 
Lung samples were kindly provided by Renate Noske-Reimers and Prof. Dr. Wolfgang Kübler 
(Charité, Institute of Physiology, Berlin, Germany). In anesthetized Sprague-Dawley rats (268 ± 6 g 
body weight), a bolus of ANP or an equivalent volume of NaCl were injected via a central venous 
catheter. ANP dosage was calculated to reach a blood concentration of 1 µM under the assumption of 
a rat blood volume of 64 ml/kg body weight.77 1 h after bolus administration lungs were excised and 
cryopreserved in liquid nitrogen. Lung tissue was cryocut and protein was extracted. Protein 
concentrations were measured by the method of Bradford.78 Western blot analysis was performed as 
described under 2.3.3. 
2.3.3 In vitro samples 
Cells were cultured in 6- or 12-well plates, grown until confluence, and treated as indicated in the 
respective figure legends. Cells were washed twice with ice-cold PBS, lysed in modified RIPA buffer 
and centrifuged. For adjusting the samples to the same protein content, protein concentration of the 
supernatant was determined by the bicinchoninic acid method (BC assay reagents, Interdim, 
Montluçon, France) (Ref). Laemmli sample buffer was added and the samples were heated at 95°C 
for 5 min. Subsequently, a denaturating discontinuous polyacrylamide gel electrophoresis (SDS-Disc-
PAGE) (Mini-Protean 3, Bio-Rad, Munich, Germany) was performed for separation of proteins. 
Proteins were blotted onto a polyvinylidene fluoride (PVDF) membrane (Immobilon-P, Millipore, 
Schwalbach, Germany) by semi-dry electro-blotting (1 h, 1.56 mA/cm2) (Bio-Rad, Munich, Germany). 
The membrane was dried for 30 min at 80°C and afterwards saturated (blocked) in 5 % non-fat dry 
milk (Bio-Rad, Munich, Germany) in TBS-T for 2 h. Incubation with the primary antibody was 
performed overnight at 4°C by gently shaking the membrane in the antibody dilution. Subsequently, 
the membrane was washed three times with TBS-T and incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibody for 2 h at room temperature. The membrane was again washed 
three times with TBS-T. For visualization of bands, an enhanced chemoluminescence detection kit 
(ECL plus, Amersham, Freiburg, Germany) was used and membranes were applied to a medical x-ray 
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film (Super RX, Fuji, Düsseldorf, Germany) or to an image station (Kodak Image Station 440cf, Kodak, 
Rocester, USA). Films were developed with an AGFA Curix 60 (AGFA, Cologne, Germany) and 
scanned for subsequent digital analysis. 
2.3.4 Stripping, reprobing, and coomassie staining 
For removing antibodies from the membrane (stripping), blots were incubated for 30 min at 50°C in a 
stripping buffer consisting of Tris-HCl 62.5 mM, SDS 2 %, and β-mercaptoethanol 0.8 %. The 
membrane was extensively washed with TBS-T and blocked for 2 h in non-fat dry milk (5 % in TBS-T). 
Subsequently, the membrane was incubated with new antibodies (reprobing) according to section 
2.3.3. To check the uniformity of protein loading and transfer, gels were stained by a protein dyeing 
solution containing coomassie brilliant blue 3 %, acetic acid 10 %, and ethanol 45 %. 
2.4 RT-PCR 
2.4.1 Isolation and characterization of total RNA 
Cells were grown in 25 cm² cell culture flasks or in 60 mm dishes until confluence. Total RNA was 
prepared using the RNA isolation RNeasy Mini Kit (Qiagen, Hilden, Germany). The cells were lysed 
and homogenized in a buffer containing β-mercaptoethanol and the chaotropic denaturating salt 
guanidine isothiocyanate. RNases are immediately inactivated by the buffer. Ethanol was added for 
creating appropriate binding conditions of RNA to the silica-gel-based membranes of the microspin 
columns. All other cellular component were removed by different washing procedures. Subsequently, 
the purified RNA was eluated under low salt conditions from the column. RNA molecules longer than 
200 nucleotides are predominantly isolated, which provides an enrichment of mRNA. The size 
distribution of the isolated RNA is comparable to that obtained by the classical RNA isolation method 
of centrifugation through a CsCl cushion. 
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The obtained amount of RNA was quantified photometrically (Lambda Bio 20 Photometer, 
PerkinElmer, Überlingen, Germany). Absorption was measured at 260 nm (A260) and 280 nm (A280). 
The RNA concentration was calculated from the A260 value. The ratio A260/A280 was used for 
characterizing the purity of RNA (optimum: 1.8-2.0). Strong absorption at 280 nm indicates protein 
contaminations. 
 
The integrity of the isolated RNA was checked by agarose gel (1.2 %) (SeaKem LE Agarose, 
BioWhittaker, Rockland, USA) electrophoresis (Owl Separation Systems, Portsmouth, USA). TAE 
consisting of Tris 40 mM, EDTA 1 mM, and acetic acid 1.1 % was used as electrophoresis buffer. 
Ethidium bromide was directly added to the agarose gel solution (final concentration 0.5 µg/ml). For 
sample loading 6x blue/orange loading dye (Promega, Heidelberg, Germany) was used. Bands were 
visualized under UV-light (254 nm) on an image station (Kodak Image Station 440cf, Kodak, 
Rochester, USA). The intensity ratio of the two major bands (ribosomal 28S and 18S RNA) was used 
to estimate RNA integrity. 
2.4.2 Reverse transcription 
Reverse transcription was performed using a reverse transcription system kit (Promega, Heidelberg, 
Germany). This kit uses the reverse transcriptase from the avian myoblastosis virus (AMV-RT). 
Samples were incubated at 42°C for 25 min. The reaction was stopped by incubation at 99°C for 
5 min. 
2.4.3 Polymerase chain reaction 
MKP-1 PCR was performed with Taq DNA polymerase from Thermophilus aquaticus (Promega, 
Heidelberg, Germany). MKP-1 primers: 5’-GCTGTGCAGCAACAGTC-3’ and 5’-TACCTTATGAGGAC-
TAATCG-3’. GAPDH primers: 5’-TCACTCAAGATTGTCAGCAA-3’ and 5’-AGATCCACGACGGACAC-
ATT-3’. PCR conditions for MKP-1: 94°C 5:00 min; (94°C 1:00 min, 57°C 2:00 min, 72°C 1:00 min) 
35 cycles; 72°C 5:00 min. PCR conditions for GAPDH: 93°C 1:06 min; (93°C 0:24 min, 55°C 
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0:30 min, 73°C 1:00 min) 30 cycles; 73°C 10:00 min. Nox1-5 RT-PCR was performed using the 
Access RT-PCR System (Promega, Heidelberg, Germany). This one-tube two-enzyme system uses 
AMV-RT and Tfl DNA polymerase from Thermus flavus. Reverse transcription was performed at 48°C 
for 45 min. Reaction was stopped by incubation at 94°C for 2 min. Nox1 primers: 
5’-TGGCTAAATCCCATCCAGTC-3’ and 5’-AGTGGGAGTCACGATCATCC-3’. Nox2 primers: 5’-TGG-
ATAGTGGGTCCCATGTT-3’ and 5’-GCTTATCACAGCCACAAGCA-3’. Nox3 primers: 5’-CCAGGGC-
AGTACATCTTGGT-3’ and 5’-CTGTGCCTCACTGCATTTGT-3’. Nox4 primers: 5’-TGTTGGATGA-
CTGGAAACCA-3’ and 5’-TGGGTCCACAACAGAAACA-3’. Nox5: 5’-CTACGTGGTAGTGGGGC- 
TGT-3’ and 5’-AACAAGATTCCAGGCACCAG-3’. PCR conditions: (94°C 0:30 min; 60°C 1:00 min,  
68°C 2:00 min) 40 cycles; 68°C 7:00 min. The PCR products were separated by agarose gel 
electrophoresis as described under 2.4.1. 
2.5 ROS measurement in cultured endothelial cells 
Dihydrofluorescein diacetate (H2FDA) was used to assess the generation of intracellular reactive 
oxygen species (ROS).79 H2FDA easily penetrates the cell membrane. Cleavage of its ester groups by 
intracellular esterases leads to the formation of the negatively charged, intracellular-trapped ROS-
sensitive dye dihydrofluorescein. Oxidation of dihydrofluorescein results in highly fluorescent 
derivatives of fluorescein. The absorption and emission spectrum of fluorescein is depicted in figure 
12. Fluorescence was measured with a SpectraFluor Plus microplate reader (Tecan, Crailsheim, 
Germany) using an excitation and emission wavelength of 485 nm and 535 nm, respectively. 
 
Cells were grown until confluence in 24- or 96-well plates and treated as indicated in the respective 
figures. After treatment, cells were washed twice with HBSS pH 7.4 consisting of NaCl 142 mM, KCl 
5.4 mM, Na2HPO4 0.28 mM, KH2PO4 0.37 mM, CaCl2 1.22 mM, MgSO4 0.81 mM, glucose 5.6 mM, 
and HEPES 20 mM. Subsequently, cells were loaded with 20 µM H2FDA (in HBSS) by incubation for 
20 min at 37°C in the dark, and washed again. All experiments were taken 30 min after treatment 
(except for time courses). 
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excitation
emission
 
 
Figure 12:  Absorption and emission spectrum of fluorescein. 
 
The validity of the ROS assay was tested by two ways: (i) Freshly isolated pig granulocytes – known 
for their ROS-producing capacity – were loaded with H2FDA as described above and treated with the 
phorbol ester PMA, a known inducer of ROS generation in phagocytes, for the indicated times (figure 
13A). (ii) HUVEC were treated with the oxidant hydrogen peroxide (figure 13B). The fluorescence 
signal clearly rose in both settings. 
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Figure 13: Validity of the ROS assay. A: Freshly isolated pig granulocytes were incubated with 20 µM H2FDA for 20 
min. Cells were treated with phorbol-12-myristate-13-acetate (PMA, 100 nM) for the indicated times. B: 
HUVEC were loaded with 20 µM H2FDA for 20 min. Hydrogen peroxide (H2O2, 100 µM) was added to the 
cells for 30 min. 
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Dihydrofluorescein is known to react with a variety of oxidants including superoxide, hydrogen 
peroxide, and peroxynitrite.79 Peroxynitrite is the reaction product of superoxide and nitrogen oxide 
(NO). To figure out whether peroxynitrite/NO is involved in the increase of the fluorescence signal 
generated by ANP, we applied the endothelial NO synthase (NOS) inhibitor NG-nitro-L-arginine  
(L-NNA). As shown in figure 14A, L-NNA only slightly decreased the ANP-induced ROS generation, 
pointing to an only marginal involvement of peroxynitrite/NO. Since the question raised whether ANP 
influences the generation of NO, an arginine/citrullin conversion assay was kindly performed by 
Thomas Räthel. Figure 14B shows that ANP does not induce endothelial NO generation. These 
results clearly indicate that peroxynitrite is not or only to an extremely low degree involved in the ANP-
induced fluorescence signal increase and, moreover, that NO needed for the generation of 
peroxynitrite does not arise from ANP-treatment, since treatment with L-NNA alone decreased the 
fluorescence signal, it much more seems to result from the basal endothelial NO pool. 
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Figure 14:  A: ROS generation. HUVEC were either left untreated (Co), treated with ANP (1 µM) or L-NNA (125 µM, 60 
min) alone, or pre-treated with L-NNA (125 µM, 60 min) before ANP (1 µM). B: Arginine/citrullin conversion 
assay. HUVEC were treated with ANP (1 µM) for the indicated times. *** P  ≤ 0.001 vs. Co. 
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2.6 ROS measurement in the endothelium of intact rat lung vessels 
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Figure 15:  Fluorescence measurement of ROS in the endothelium of isolated-perfused rat lung vessels. 
 
The experiments described in this section were kindly performed by Corinna Brückl (Institute for 
Surgical Research, University of Munich, Germany) and Dr. Wolfgang Kübler (Institute of Physiology, 
Charité – Medical School of the Berlin Universities, Campus Benjamin Franklin, Germany). 
2.6.1 Animals 
Male Sprague-Dawley rats (487 ± 20 g body weight) were obtained from the local breeding facilities of 
the academical institution. All animals received care in accordance with the ”Guide for the Care and 
Use of Laboratory Animals“ (NIH publication no. 85-23, rev. 1985), and the study was approved by the 
animal care and use committees of the local government authorities. 
2.6.2 Isolated-perfused rat lung preparation 
Lungs excised from anesthetized Sprague-Dawley rats were continuously perfused with 14 ml/min 
autologous rat blood at 37°C. Lungs were constantly inflated at positive airway pressure of 5 cmH2O 
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with a gas mixture of 21 % O2, 5 % CO2, an 74 % N2, that maintained blood PO2 (140 mmHg), 
PCO2 (35 mmHg), and pH (7.4) (Chiron Diagnostics, Fernwald, Germany). Left atrial pressure was 
adjusted to 5 cmH2O, yielding pulmonary artery pressures of 10 ± 1 cmH2O. PPA and PLA were 
continuously monitored (Servomed SMS 308; Hellige, Freiburg, Germany) and displayed on a 
multichannel recorder (Oscilloreg, Siemens, Erlangen, Germany). Lungs were positioned on a custom-
built vibration-free table and superfused with normal saline at 37°C to prevent drying. For local delivery 
of fluorescent probes and drugs to pulmonary microvessels in situ, a microcatheter (Ref. 800/110/100, 
SIMS Portex Ltd., Kent, UK) was advanced through the left atrium and wedged in a pulmonary vein 
draining a capillary area on the lung surface.80,81 For a schematic overview of the experimental setting 
see figure 15. 
2.6.3 In situ fluorescence microscopy 
In isolated-perfused rat lungs, ROS production was determined by digital fluorescence imaging of lung 
capillary endothelial cells loaded with the ROS-sensitive dye H2DCF.82 Membrane-permeable H2DCF 
diacetate (2 µM), which de-esterifies intracellularly to cell-impermeable H2DCF, was infused into 
pulmonary venular capillaries using the venous microcatheter. Endothelial H2DCF fluorescence was 
excited by near monochromatic illumination from a galvanometric scanner (Polychrome II, TILL 
Photonics, Martinsried, Germany) at 488 nm. The excitation light was directed through an Olympus 
BX50 upright microscope equipped with appropriate dichroic and emission filters (Olympus Optical 
Co., Hamburg, Germany). Fluorescence emission was collected through an apochromat objective 
(UAPO 40x W2/340, Olympus Optical Co.) by a CCD camera (Imago, TILL Photonics), stored on a 
personal computer and subjected to digital image analysis (TILLvisION 4.0, TILL Photonics). 
Fluorescence images of single subpleural capillaries were obtained in 5 s intervals, and exposure time 
for a single image was limited to 7 milliseconds. Off-line, images were corrected for background as 
determined over alveolar spaces. Throughout experiments, the fluorescence background remained 
unchanged. Single venular capillaries were viewed at a focal plane corresponding to their maximum 
diameter (12-25 µm). Although the only cell type in the vascular wall of these capillaries are 
endothelial cells,83 fluorescent dyes may leak across the endothelial layer to enter adjacent cells such 
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as epithelial cells of juxtaposed alveoli or enter blood cells such as leukocytes or platelets. To avoid 
these potential pitfalls, we maintained absorptive conditions within the capillary and cleared the 
capillary of blood before dye infusion.84 
2.7 Electrophoretic mobility shift assay (EMSA) 
2.7.1 Extraction of nuclear protein 
HUVEC were grown in 6-well plates until confluence and were treated as indicated in the respective 
figures. Nuclear extracts were prepared according to the method of Schreiber et al.85 as follows: after 
treatment, cells were washed twice with ice-cold PBS, scraped off in PBS with a rubber cell scraper, 
centrifuged, and resuspended in an ice-cold buffer containing N-(2-hydroxyethyl)piperazine-N’-(2-
ethanesulfonic acid) (HEPES) pH 7.9 10 mM, KCl 10 mM, EDTA 0.1 mM, ethylene glycol-O,O’-bis-(2-
amino-ethyl)-N,N,N’,N’,-tetraacetic acid (EGTA) 0.1 mM, dithio-1,4-threitol (DTT) 1 mM, PMSF 0.5 
mM, and Complete® 1 %. Cells were incubated on ice for 15 min. Nonidet P-40 was added to the cells 
and after vigorous vortexing the homogenate was centrifuged. The nuclear pellet was resuspended by 
vigorous rocking for 15 min at 4°C in a buffer containing HEPES pH 7.9 20 mM, NaCl 400 mM, EDTA 
1 mM, EGTA 0.5 mM, glycerol 25 %, DTT 1 mM, PMSF 1 mM, and Complete® 2 %. The nuclear 
extract was centrifuged and the supernatant containing nuclear proteins was frozen at -80°C. The 
protein concentrations were determined by the method of Bradford.78 
2.7.2 Radioactive labeling of consensus oligonucleotides 
Double-stranded oligonucleotide probes containing the consensus sequence either for AP-1 (5’-
CGCTTGATGAGTCAGCCGGAA-3’) or for NF-κB (5’-AGTTGAGGGGACTTTCCCAGGC -3’) (both 
from Promega, Mannheim, Germany) were 5’-end-labeled with adenosine 5’-[γ-32P]triphosphate (3,000 
Ci/mmol) (Amersham, Freiburg, Germany) by using the T4 polynucleotide kinase (PNK) (USB, 
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Cleveland, USA), which catalyzes the transfer of the terminal phosphate of ATP to the 5’-hydroxyl 
termini of DNA. The oligonucleotides were incubated with T4 PNK for 10 min at 37°C and the reaction 
was stopped by adding EDTA-solution (0.5 M). The radiolabeled DNA was separated from unlabeled 
remnants by using NucTrap probe purification columns (Stratagene, La Jolla, USA). Radiolabeled 
DNA was eluated from the column by STE buffer pH 7.5 containing Tris-HCl 10 mM, NaCl 100 mM, 
and EDTA 1 mM and frozen at -20°C. 
2.7.3 Binding reaction and electrophoretic separation 
5x binding buffer pH 7.5 is composed of glycerol 20 %, MgCl2 5 mM, EDTA 2.5 mM, NaCl 250 mM, 
and Tris-HCl 50 mM. Gel loading buffer pH 7.5 consists of Tris-HCl 250 mM, bromphenolblue 0.2 %, 
and glycerol 40 %. The reaction buffer contains DTT 2.6 mM, 5x binding buffer 90%, and gel loading 
buffer 10 %. 10x TBE pH 8.3 is composed of Tris 0.89 M, boric acid 0.89 M, and EDTA 0.02 M. 
 
Equal amounts of nuclear protein (approx. 2 µg) were incubated for 5 min at room temperature in a 
total volume of 14 µl containing poly(dIdC) 2 µg and reaction buffer 3 µl. Subsequently, 1 µl of the 
radiolabeled oligonucleotide probe (approx. 300,000 cpm) was added. After incubation for 30 min at 
room temperature, the nucleoprotein-oligonucleotide complexes were resolved by electrophoresis 
(Mini-Protean 3, Bio-Rad, Munich, Germany) on non-denaturating polyacrylamide gels (4.5 %) 
containing 10x TBE 5.3 %, acrylamide 30 %-bisacrylamide 0.8 %-solution (rotiphorese Gel 30) 
15.8 %, glycerol 2.6 %, TEMED 0.05 %, and APS 0.08 %. TBE was used as electrophoresis buffer. 
Bands were visualized by applying the gels to Cyclone Storage Phosphor Screens (Canberra-
Packard, Dreieich, Germany) and analysis by a phosphorimager (Cyclone Storage Phosphor System, 
Canberra-Packard, Dreieich, Germany). 
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2.8 Transfection experiments 
2.8.1 Rac1 mutants 
The plasmids pcDNA3.1 (Invitrogen, Karlsruhe, Germany), pcDNA3RacN17-myc (containing an insert 
coding for myc-tagged RacN17, a dominant negative Rac1 mutant), and pcDNA3RacV12-myc 
(containing an insert coding for myc-tagged RacV12, a constitutively active Rac1 mutant) were kindly 
provided by Dr. Agnes Görlach (German Heart Center, Munich). HMEC were grown to 40-80 % 
confluence in 6- or 24-well plates and were transfected with the contructs by using SuperFect 
Transfection Reagent (Qiagen, Hilden, Germany). SuperFect is an activated dendrimer with a defined 
spherical structure with branches radiating from a central core and terminating at charged amino 
groups. The DNA is assembled by SuperFect into compact structures. DNA/SuperFect-complexes are 
positively charged which allows them to bind to negatively charged receptors (e.g. glyoproteins) on the 
eukaryotic cell surface. Following endocytosis, SuperFect buffers the lysosome after fusion with the 
endosome, leading to pH inhibition of lysosomal nucleases and stability of DNA/SuperFect-complexes. 
For 6-well plates 2 µg DNA and 10 µl SuperFect and for 24-well plates 1 µg DNA and 5 µl SuperFect 
were used. The DNA was incubated with SuperFect for 10 min at ambient temperature. Cells were 
treated with the DNA/SuperFect-complex for 2 h. To ensure a sufficient expression of the Rac1 mutant 
proteins, further treatments were started 48 h after transfection. 
2.8.2 Antisense oligodesoxynucleotides 
Transfection of antisense oligodesoxynucleotides (ODN) is used to silence the expression of a distinct 
gene. To prevent the transfected ODN from degradation, phosphorothioate-modified ODN are used. 
The antisense sequences were for MKP-1 5’-ggtccCGAATGTGCTGagttc-3’, for gp91phox/Nox2 
5’-cctcatTCACAGCGcagtt-3’,86 and for Nox4 5’-ggacaCAGCCATGccgcc-3’.62 Lower case letters 
represent phosphorothioate modifications. Control experiments were performed with the respective 
sense sequence. For transfection of the ODN, jetPEI transfection reagent (Polyplus-
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Transfection/Biomol, Hamburg, Germany) was used. jetPEI is a linear polyethylenimine and compacts 
DNA into positively charged particles capable of interacting with anionic proteoglycans at the cell 
surface and entering cells by endocytosis. jetPEI buffers the endosomal pH and protects DNA from 
degradation. It also induces osmotic swelling and rupture of the endosome, which provides an escape 
mechanism for DNA particles to the cytoplasm. HUVEC were cultured until approx. 80 % confluence in 
6- or 24-well plates. For 6-well plates 5 µg DNA and 10 µl jetPEI and for 24-well plates 3 µg DNA and 
6 µl jetPEI were used. The DNA was incubated with jetPEI for 30 min at ambient temperature. Cells 
were treated with the DNA/jetPEI-complex for 4 h. To ensure a sufficient silencing of the targeted 
proteins, further experiments were started 24 h after transfection. 
2.8.3 AP-1 decoy 
An AP-1 decoy is an oligonucleotide consisting of the consensus sequence of the transcription factor 
AP-1. Therefore, the decoy is capable of catching the activated transcription factor leading to an 
inactivation of the AP-1 response. The decoy sequences were as follows: AP-1 decoy 
5’-cgctTGATGACTCAGCCggaa-3’ and AP-1 scrambled decoy 5’-cgctTGATGACTTGGCCggaa-3’.87 
Lower case letters represent phosphorothioate modifications. AP-1 decoys were transfected into 
HUVEC with SuperFect according to section 2.8.1. Experiments were performed 4 h after transfection. 
2.9 Rac pull-down assay 
2.9.1 Principle of the assay 
The affinity precipitation assay detecting active Rac1 uses the p21-binding domain (PBD) of the Rac1 
target p21-activated kinase 1 (PAK1) fused to glutathione S-transferase (GST) to isolate a complex 
containing GST-PBD bound to active Rac1 (Rac-GTP). The GST-PBD fusion protein is bound to 
glutathione sepharose beads, which allows the precipitation of the complex (figure 16). 
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Figure 16:   Schematic depiction of the Rac pull-down assay. The assay allows to specifically isolate active Rac (i.e. 
Rac-GTP) from cell lysates. Abbreviations: glutathione S-transferase (GST), p21-binding domain (PBD). 
2.9.2 Preparation of the GST-PBD sepharose beads 
GST-PBD sepharose beads were prepared according to Benard et al.88 as follows: E. coli transformed 
with pGEX-4T-3 – a cloning vector for the inducible expression of genes (lac promotor) as GST fusion 
proteins – containing the information for PBD were kindly provided by Dr. Ulla Knaus (The Scripps 
Research Institute, La Jolla, USA). E. coli transformed with pGEX-4T-3PBD were cultured at 37°C 
overnight in 100 ml LB broth medium containing ampicillin (100 µg/ml) in a shaker for bacteria. The 
100 ml-culture was added to 1,900 ml LB broth medium containing ampicillin and the bacteria were 
allowed to grow for 90 min at 37°C. The optical densitiy (OD) at 600 nm was taken to check whether 
the bacteria expanded to a sufficient quantity (optimal OD600: 0.9). To induce the expression of the lac 
promoter-linked GST-PBD gene, isopropyl-β-D-thiogalactopyranoside (IPTG) was added to the culture 
to a final concentration of 0.3 mM. Bacteria were allowed to express the GST-PBD fusion protein for 3 
h at 30°C. After centrifugation, the bacteria pellet was lysed in a buffer containing Tris pH 7.5 50 mM, 
NaCl 150 mM, MgCl2 5 mM, DTT 1 mM, PMSF 1 mM, EDTA 1 mM, leupeptin 1 µg/ml, and aprotinin 
10 µg/ml. The lysate was homogenized by sonication and centrifuged. The supernatant was incubated 
with a glutathione sepharose bead suspension (Amersham, Freiburg, Germany) for 60 min at 4°C. 
Beads were washed five times with a buffer containing Tris pH 7.5 50 mM, NaCl 50 mM, MgCl2 5 mM, 
EDTA 1 mM, DTT 0.1 mM, and PMSF 0.1 mM. Different samples were taken during the purification 
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procedure and analyzed by Western blot analysis and Coomassie staining of the gel in order to judge 
the purity of the GST-PBD bead suspension and the degree of GST-PBD binding to the beads (figure 
17). 
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Figure 17:  Coomassie-stained control gel. Lane 1: total bacterial lysate. Lane 2: lysate after bead incubation. Lane 3: 
supernatant after two bead washing steps. Lane 4: 5 µl beads. Lane 5: 10 µl beads. The arrows mark the 
GST-PBD band. 
2.9.3 Pull-down assay 
The Rac1 pulldown assay was performed according to Benard et al.88 as follows: HUVEC were grown 
in 100 mm dishes until confluence and treated as indicated in the respective figure legend. Cells were 
washed once with ice-cold PBS and lysed either with PBD-buffer containing Tris pH 8.0 25 mM, DTT 1 
mM, MgCl2 20 mM, NaCl 100 mM, EDTA 0.5 mM, and Triton X-100 1 % or with GTPγS-PBD-buffer 
containing Tris pH 8.0 25 mM, DTT 1 mM, MgCl2 5 mM, NaCl 100 mM, EDTA 1 mM, and Triton X-100 
1 %. After scraping cells off with a rubber cell scraper, cells were incubated for complete lysis for 
15 min at 4°C under vigorous shaking. The cell lysate was centrifuged and the supernatant was frozen 
at -80°C. Protein concentration was determined using the bicinchoninic assay method. 200 µg protein 
was used for the pull-down assay. 
 
As a positive control specific samples were incubated for 10 min at 30°C with GTPγS (10 mM) and 
EDTA (100 mM), leading to an exchange of Rac-GDP to Rac-GTP. The exchange reaction was 
stopped by adding MgCl2 (1 M). 
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The pull-down assay was performed by gently shaking the samples with the GST-PBD beads for 1 h 
at 4°C. After centrifugation, the bead-pellet was washed five times with PBD-buffer. The beads were 
resuspended in 1x Laemmli sample buffer (see section 2.3.1) and boiled for 5 min at 95°C. Western 
blot analysis was performed as described under 2.3.2. 
2.10 Immunocytochemistry and confocal microscopy 
HUVEC were grown until confluence on collagen-coated (collagen 1 % in PBS) glass coverslips 
(∅ 12 mm) in 24-well plates. Cells were treated as indicated in the respective figure legend. After 
treatment cells were washed with PBS+ and fixed with a buffered formaldehyde solution (4 %) for 
15 min. Cells were washed with PBS and permeabilized with Triton X-100 (0.2 %) for 2 min. After 
washing three times with PBS, unspecific binding was blocked by incubating cells with a bovine serum 
albumin (BSA) solution (0.2 %) for 15 min in order to minimize non-specific adsorption of antibodies. 
Cells were incubated with the primary antibody (1 µg/ml) for 1 h, washed three times with PBS, and 
subsequently incubated with the secondary antibody (5 µg/ml) for 30 min. Cells were again washed 
three times with PBS. The coverslips were embedded in fluorescent mounting medium 
(DakoCytomation, Hamburg, Germany) and put onto glass objective slides. Images were obtained 
using a Zeiss LSM 510 META (Zeiss, Oberkochen, Germany) confocal laser scanning microscope. 
2.11 Flow cytometry (FACS) 
Cells were grown until confluence in 24-well plates and were treated as indicated in the respective 
figure legend. After treatment, cells were washed with PBS, detached by trypsinization as described 
under 2.2.3, and transferred into FACS tubes containing a buffered formaldehyde solution (4 %), 
which stopped trypsinization. Cells were incubated for 15 min in the formaldehyde solution for fixation. 
Subsequently, cells were washed with PBS and incubated with a fluorescent dye-labeled antibody in 
the dark for 20 min. After washing, cells were resuspended in PBS for flow cytometric analysis 
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(FACSCalibur, BD Biosciences, Heidelberg, Germany). The FACS buffer pH 7.37 consisted of NaCl 
138.95 mM, KH2PO4 1.91 mM, Na2HPO4 16.55 mM, KCl 3.76 mM, LiCl 10.14 mM, NaN3 3.08 mM, 
and EDTA 0.967 mM. 
2.12 Statistical analysis 
All experiments were done from at least two to three different cell preparations (n ≥ 2). Each 
experiment was performed at least in duplicates. Data are expressed as mean ± SEM. Statistical 
analysis was performed with GraphPad Prism 3.03. Unpaired t-test was used to compare two groups. 
To compare three or more groups, one-way ANOVA followed by Tukey’s post test was used. Data 
gathered from ROS measurements in rat lungs were analyzed by Mann-Whitney U-test.  
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3.1 ANP and MKP-1 
3.1.1 MKP-1 induction by ANP 
3.1.1.1 Time and concentration course of MKP-1 induction 
The induction of MKP-1 by ANP in HUVEC has previously been shown by Dr. Nina Weber.14 We 
confirmed these experiments both in HUVEC and in HMEC (figure 18A,C): ANP rapidly increased 
endothelial MKP-1 protein expression. This induction persists for approx. 90 min. Performing an ANP 
concentration course (figure 18B), we observed a slight protein induction already at 0.1 nM. For further 
experiments, 1 µM was used as standard concentration for ANP. 
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Figure 18:  Time- and concentration-course of ANP-induced MKP-1 expression. Control (Co) cells were left untreated. 
A: HUVEC were treated with ANP (1 µM) for the indicated times. B: HUVEC were treated with ANP for 60 
min (concentration as indicated). C: HMEC were treated with ANP (1 µM) for the indicated times. MKP-1 
protein expression was determined by Western blot analysis as described in section 2.3.3. 
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3.1.1.2 Influence of cycloheximide on MKP-1 induction 
To clarify whether the upregulation of MKP-1 by ANP depends on de novo protein biosynthesis, we 
used cycloheximide, an inhibitor of translation, and found that the ANP-induced MKP-1 induction was 
completely suppressed after 30 min (figure 19), whereas the early induction at 15 min was not affected 
by cycloheximide. These findings indicate that ANP activates MKP-1 protein de novo synthesis within 
30 min and, moreover, suggest that the early effect of ANP might be independent from protein 
synthesis. 
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Figure 19:  Effect of cycloheximide on ANP-induced MKP-1 expression. HUVEC were treated with ANP (1 µM) for the 
indicated times in the presence of cycloheximide (10 µg/ml, 30 min before ANP). MKP-1 protein expression 
was determined by Western blot analysis as described in section 2.3.3. 
 
3.1.1.3 MKP-1 induction depends on cGMP/NPR-A 
The effects of ANP can be mediated by two different receptors: NPR-A or NPR-C. We wanted to 
clarify which receptor participates in the induction of MKP-1 by ANP. Therefore, we treated HUVEC 
with 8-Br-cGMP, a cell-permeable analogue of the NPR-A-dependent second messenger of ANP. We 
observed that 8-Br-cGMP mimicked the effect of ANP on MKP-1 protein expression (figure 20), 
whereas cANF, a specific agonistic ligand of NPR-C, did not alter MKP-1 levels (figure 20). Our data 
indicate that MKP-1 upregulation by ANP is mediated via cGMP/NPR-A. 
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Figure 20:  Receptor specificity of MKP-1 induction. HUVEC were treated with ANP (1 µM), 8-Br-cGMP, and cANF 
(concentrations as indicated) for 60 min. MKP-1 protein expression was determined by Western blot 
analysis as described in section 2.3.3. 
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3.1.1.4 PKG I is not expressed in HUVEC 
Since we found that cGMP is the crucial mediator for the induction of MKP-1 by ANP, we wanted to 
check whether a central downstream target of cGMP, the cGMP-dependent protein kinase I (cGKI, 
PKG I), is a mediator of ANP’s effect on MKP-1 expression. We used different HUVEC cell 
preparations (primary culture and passages no. 1-3) in order to investigate the expression of PKG I at 
the protein level. PKG I-transfected COS cells were used as positive control. Figure 21 indicates that 
HUVEC do not express PKG I protein. 
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Figure 21:  HUVEC do not express PKG I protein. 50 µg protein of HUVEC cell lysate obtained from primary culture 
(prim.) or passage no. 1-3 (#1-3) were analyzed by Western blot analysis as described in section 2.3.3. 
PKG I-transfected COS cells served as positive control (pos.). 
 
3.1.2 ANP induces endothelial ROS production 
3.1.2.1 Time and concentration course of ROS generation 
Since reactive oxygen species (ROS) have been described as inducers of MKP-1, we hypothesized 
that ROS generation could account for an induction of MKP-1 by ANP. However, nothing has as yet 
been known about the capability of ANP to induce the generation of ROS in endothelial cells. 
Therefore, we measured intracellular ROS formation by loading HUVEC with an ROS-sensitive 
fluorescent dye. Different control experiments were performed in order to ensure the validity of the 
used dye (see section 2.5). Treatment of HUVEC with ANP led to an increased ROS production with a 
maximum dye fluorescence at about 30 min (figure 22A). The concentration dependency of this effect 
is shown in figure 22B. 
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Figure 22:  ROS generation induced by ANP. A: ANP time course. HUVEC were treated with ANP (1 µM) for the 
indicated times. B: ANP concentration course. HUVEC were treated with the indicated concentrations of 
ANP. ROS generation was measured as described in section 2.5. * P  ≤ 0.05 vs. Co. 
 
3.1.2.2 ROS generation depends on cGMP/NPR-A. 
In analogy to the experiments regarding the induction of MKP-1 protein, we checked whether 8-Br-
cGMP and cANF affect ROS generation in HUVEC. cANF did not significantly alter ROS levels, 
whereas 8-Br-cGMP clearly induced the production or ROS (figure 23). These data suggest that ANP 
induces endothelial ROS production via the cGMP/NPR-A-pathway. 
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Figure 23:  Effect of 8-Br-cGMP and cANF on ROS generation. HUVEC were treated with the indicated concentration of 
8-Br-cGMP and cANF. ROS formation was measured as described in section 2.5. * P  ≤ 0.05 vs. Co. 
 
Results 47 
3.1.3 ROS mediate the induction of MKP-1 by ANP 
3.1.3.1 Antioxidants abrogate ANP-induced MKP-1 expression 
We aimed to causally link ANP-induced ROS generation and MKP-1 expression. Therefore, we 
treated HUVEC with different antioxidants: tiron (a scavenger of superoxide), ebselen (a scavenger of 
peroxynitrite and peroxides), and N-acetyl-L-cysteine (a thiol-based antioxidant). All used substances 
were able to abrogate the ANP-induced MKP-1 expression (figure 24), pointing to a pivotal role for 
ROS in the upregulation of MKP-1 by ANP. 
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Figure 24:  Antioxidants abolish the induction of MKP-1 by ANP. HUVEC were pre-incubated with the antioxidants tiron 
(10 mM), ebselen (40 µM), and N-acetyl-L-cysteine (NAC, 10 mM) for 60 min before adding ANP (1 µM, 60 
min). MKP-1 protein expression was determined by Western blot analysis as described in section 2.3.3. 
 
3.1.3.2 Hydrogen peroxide induces MKP-1 
We tested whether the exogenous administration of an oxidant is capable of augmenting MKP-1 levels 
in HUVEC. We added hydrogen peroxide (H2O2) to the cells and found a clear increase of MKP-1 
protein expression with a maximum at 60 min (figure 25). 
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Figure 25:  Hydrogen peroxide induces MKP-1 expression. HUVEC were either left untreated (Co) or were treated with 
hydrogen peroxide (H2O2, 50 µM) for the indicated times. MKP-1 protein expression was determined by 
Western blot analysis as described in section 2.3.3. 
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3.1.4 Involvement of NAD(P)H oxidase 
The superoxide-generating NAD(P)H oxidase (Nox) represents a major source of ROS production in 
endothelial cells. We intended to clarify whether NAD(P)H oxidase is involved in ANP-induced ROS 
formation and, moreover, which Nox isoforms are responsible for the observed effects, i.e. increased 
ROS formation and MKP-1 protein expression upon ANP-treatment. 
3.1.4.1 Influence of PEG-SOD and SOD on ANP-induced ROS generation 
First, we aimed to specify which reactive oxygen species is generated in HUVEC upon ANP-
treatment. We treated HUVEC with a pegylated superoxide dismutase (PEG-SOD), a stable and cell-
permeable derivative of the superoxide-catabolizing enzyme SOD. As shown in figure 26A, PEG-SOD 
completely abrogated the ANP-induced fluorescence signal. Treatment with cell-impermeable SOD 
did not influence the ANP-induced generation of ROS (figure 26B). These findings suggest that 
intracellular superoxide is produced by HUVEC upon ANP-treatment. 
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Figure 26:  Influence of PEG-SOD and SOD on ANP-induced ROS generation. A: HUVEC were left untreated (Co), 
were treated with ANP (1 µM) or pegylated superoxide dismutase (PEG-SOD, 300 U/ml, 60 min) alone, or 
were pre-treated with PEG-SOD (300 U/ml, 60 min) before ANP (1 µM). B: HUVEC were left untreated (Co), 
were treated with ANP (1 µM) or SOD (300 U/ml, 60 min) alone, or were pre-treated with SOD (300 U/ml, 60 
min) before ANP (1 µM). ROS generation was measured as described in section 2.5. * P  ≤ 0.05 vs. Co. 
† P ≤ 0.05 vs. ANP. 
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3.1.4.2 Influence of PEG-catalase and catalase on ANP-induced ROS generation 
Intracellularly produced superoxide is rapidly degraded to hydrogen peroxide (H2O2). Besides 
superoxide, H2O2 is also able to oxidize the dye used for ROS measurements (see section 2.5). To 
investigate an involvement of H2O2, we treated HUVEC with catalase (degrades H2O2) and PEG-
catalase, the stable, cell-permeable modification of catalase. Figure 27 shows that neither PEG-
catalase (A) nor catalase (B) altered the ANP-induced fluorescence signal, suggesting no involvement 
of hydrogen peroxide. 
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Figure 27:  Influence of PEG-catalase and catalase on ANP-induced ROS generation. A: HUVEC were left untreated 
(Co), were treated with ANP (1 µM) or pegylated (PEG)-catalase (3,000 U/ml, 60 min) alone, or were pre-
treated with PEG-catalase (3,000 U/ml, 60 min) before ANP (1 µM). B: HUVEC were left untreated (Co), 
were treated with ANP (1 µM) or catalase (3,000 U/ml, 60 min) alone, or were pre-treated with catalase 
(3,000 U/ml, 60 min) before ANP (1 µM). ROS generation was measured as described in section 2.5. 
* P  ≤ 0.05 vs. Co. 
 
3.1.4.3 Influence of DPI and gp91ds-tat on ANP-induced ROS generation 
We intended to figure out whether NAD(P)H oxidase is involved in the production of superoxide upon 
ANP-treatment by using Nox inhibitors: both the nonspecific inhibitor DPI (inhibitor of flavin-containing 
enzymes) (figure 28A) and the highly specific inhibitor peptide gp91ds-tat (prevents the activation of 
Nox by inhibiting the association of Nox1/2/4 and p47phox) (figure 28B) abolished the increase of ROS 
by ANP in HUVEC. These findings clearly point to NAD(P)H oxidase as the crucial ANP-activated 
ROS source. 
50 Results 
0
10
20
-50
-40
R
O
S 
ge
ne
ra
tio
n
(%
 fl
uo
re
sc
en
ce
 in
cr
ea
se
)
R
O
S 
ge
ne
ra
tio
n
(%
 fl
uo
re
sc
en
ce
 in
cr
ea
se
)
DPI+-+-
ANP++--
†
*
-40
-20
0
20
40
R
O
S 
ge
ne
ra
tio
n
(%
 fl
uo
re
sc
en
ce
 in
cr
ea
se
)
gp91ds-tat+-+-
scramb-tat-+-+
ANP++--
*
†
BA
 
Figure 28:  Influence of DPI and gp91ds-tat on ANP-induced ROS generation. A: HUVEC were left untreated (Co), 
were treated with ANP (1 µM) or diphenyleneiodonium (DPI, 10 µM, 60 min) alone, or were pre-treated with 
DPI (10 µM, 60 min) before ANP (1 µM). B: HUVEC were treated with the NAD(P)H oxidase inhibitor 
peptide gp91ds-tat (100 µM, 30 min) or the scrambled peptide scramb-tat (100 µM, 30 min) alone or in 
combination with ANP (1 µM). ROS generation was measured as described in section 2.5. * P  ≤ 0.05 vs. 
Co. † P ≤ 0.05 vs. ANP. 
 
3.1.4.4 Influence of PEG-SOD and SOD on ANP-induced MKP-1 expression 
In order to link superoxide generation to MKP-1 induction, we tested whether treatment of HUVEC 
with PEG-SOD or SOD influences the increase of MKP-1 protein expression by ANP. In line with the 
results obtained for ROS generation, the upregulation of MKP-1 by ANP was completely blocked in 
the presence of PEG-SOD, whereas SOD did not affect MKP-1 protein levels (figure 29). These data 
suggest that intracellular superoxide is crucial for the ANP-induced augmentation of MKP-1. 
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Figure 29:  Influence of PEG-SOD and SOD on ANP-induced MKP-1 protein expression. A: HUVEC were pre-treated 
with pegylated superoxide dismutase (PEG-SOD, 300 U/ml, 60 min) before ANP (1 µM, 60 min). B: HUVEC 
were pre-treated with SOD (300 U/ml, 60 min) before ANP (1 µM, 60 min). MKP-1 protein expression was 
determined by Western blot analysis as described in section 2.3.3. 
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3.1.4.5 Influence of PEG-catalase and catalase on ANP-induced MKP-1 expression 
Since we found that H2O2 is not involved in the increase of ROS generation upon ANP-treatment, we 
wanted to investigate whether scavenging of H2O2 alters ANP-induced MKP-1 expression. In analogy 
to the ROS measurements, we treated HUVEC with PEG-catalase and catalase. As figure 30 shows, 
neither PEG-catalase nor catalase did affect the increase of MKP-1 protein upon ANP-treatment. 
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Figure 30:  Influence of PEG-catalase and catalase on ANP-induced MKP-1 protein expression. A: HUVEC were pre-
treated with pegylated (PEG)-catalase (3,000 U/ml, 60 min) before ANP (1 µM, 60 min). B: HUVEC were 
pre-treated with catalase (3,000 U/ml, 60 min) before ANP (1 µM, 60 min). MKP-1 protein expression was 
determined by Western blot analysis as described in section 2.3.3. 
 
3.1.4.6 Influence of DPI and apocynin on ANP-induced MKP-1 expression 
Furthermore, we examined the influence of the Nox inhibitors DPI and apocynin on ANP-induced 
MKP-1 expression. Both inhibitors clearly abrogated ANP’s ability to increase MKP-1 protein levels in 
HUVEC (figure 31), suggesting a pivotal role for NAD(P)H oxidase in the upregulation of MKP-1 by 
ANP. 
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Figure 31:  Influence of DPI and apocynin on ANP-induced MKP-1 expression. HUVEC were treated with DPI (10 µM, 
60 min) or apocynin (0.5 mM, 30 min) alone or in combination with ANP (1 µM, 60 min). MKP-1 protein 
expression was determined by Western blot analysis as described in section 2.3.3. 
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3.1.4.7 Expression of Nox homologues’ transcripts in HUVEC and HMEC 
Different homologues of the proto-typical catalytic subunit gp91phox/Nox2 have been discovered in the 
recent years: Nox1-Nox5. The expression pattern of these Nox homologues seems to strongly depend 
on the examined cell-type. We wanted to check which Nox homologues are expressed both in HUVEC 
and HMEC. Therefore, we investigated Nox1-5 mRNA expression by RT-PCR and found that only 
Nox2 and Nox4 mRNA are expressed both in HUVEC and HMEC (figure 32). 
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Figure 32: Expression of mRNA of Nox homologues in HUVEC and HMEC. RT-PCR was performed as described in 
section 2.4. 
 
3.1.4.8 Influence of Nox2 and Nox4 antisense on ANP-induced ROS generation 
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Figure 33:  Influence of Nox2 and Nox4 antisense oligodesoxynucleotides (ODN) on ANP-induced ROS generation. A: 
HUVEC were either left untreated or were treated with ANP (1 µM) in the presence of Nox2 sense or 
antisense ODN. B: HUVEC were either left untreated or were treated with ANP (1 µM) in the presence of 
Nox4 sense or antisense ODN. Transfection with sense or antisense ODN was performed as described in 
section 2.8.2. ROS generation was measured as described in section 2.5. * P  ≤ 0.05 vs. Co. † P ≤ 0.05 vs. 
ANP. 
 
Since we revealed that Nox2 and Nox4 are the only expressed Nox homologues, we aimed to clarify 
which isoform is involved in the generation of superoxide after ANP treatment. Therefore, we 
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transfected HUVEC with well-established Nox2 or Nox4 antisense oligodesoxynucleotides. Figure 33 
shows that the ANP-induced increase of the fluorescence signal is strongly reduced in the presence of 
Nox2 antisense (A), whereas Nox4 antisense (B) did not alter ROS generation. 
 
3.1.4.9 Influence of Nox2 and Nox4 antisense on ANP-induced MKP-1 expression 
We then aimed to clarify whether Nox2/4 antisense does also influence the ANP-induced expression 
of MKP-1. Again, HUVEC were transfected with the antisense oligos. The functionality of the 
antisense oligos, i.e. the strong reduction of the Nox2/4 protein content, is shown in the upper panels 
of figure 34A,B. According to the results presented above, the upregulation of MKP-1 by ANP was 
completely abolished in the presence of Nox2 antisense, whereas Nox4 antisense oligos did not alter 
MKP-1 protein levels (figure 34A,B, lower panels) 
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Figure 34:  Influence of Nox2 and Nox4 antisense oligodesoxynucleotides (ODN) on ANP-induced MKP-1 expression. 
A: HUVEC were either left untreated (Co) or were treated with ANP (1 µM, 60 min) in the presence of Nox2 
sense or antisense ODN. B: HUVEC were either left untreated (Co) or were treated with ANP (1 µM, 60 
min) in the presence of Nox4 sense or antisense ODN. Transfection with sense or antisense ODN was 
performed as described in section 2.8.2. MKP-1 protein expression was determined as described in section 
2.3.3. 
 
3.1.5 Involvement of Rac1 
3.1.5.1 ANP activates Rac1 
The small Rho-GTPase Rac plays an important role in the activation of phagocyte-type NAD(P)H 
oxidase and might also be involved in the activation of endothelial Nox. Since ANP-treatment of 
HUVEC had led to an activation of Nox, the question arose whether ANP could influence the activity of 
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Rac1. In order to clarify this question, we performed Rac1 pull-down assays. This assay allows to 
specifically precipitate the activated form of Rac1, i.e. Rac1-GTP. HUVEC were treated with ANP and 
the amount of activated Rac1 was analyzed. As shown in figure 35 (upper panel) we found an 
increase of active Rac1 with a maximum at 2-5 min after ANP-treatment. 
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Figure 35: ANP leads to an activation of Rac1. HUVEC were either left untreated (Co) or were treated with ANP (1 µM) 
for the indicated times. Activation of Rac1 by GTPγS serves as positive control. Rac pull-down assay was 
performed as described in section 2.9. The uniformity of the amount of total Rac1 is shown in the lower 
panel. The amounts of Rac1 protein were determined by Western blot analysis as described in section 
2.3.3. 
 
3.1.5.2 ANP induces Rac1 translocation 
As a second marker for Rac1 activity we investigated Rac1 translocation by confocal microscopy, 
since Rac1 translocates to the plasma membrane upon activation. Figure 36 shows that ANP was 
able to mimic the Rac1 translocation observed by treating HUVEC with the known Rac1 activator 
phorbol-12-myristate-13-acetate (PMA). 
PMA 5 minANP 5 minCo
50 µm 50 µm50 µm
 
Figure 36: ANP leads to a translocation of Rac1. HUVEC were either left untreated (Co) or were treated with ANP (1 
µM) or phorbol-12-myristate-13-acetate (PMA, 1 µM) for the indicated times. Rac1 translocation to the 
plasma membrane is indicated by arrows. Immuncytochemistry and confocal microscopy were performed as 
described in section 2.10. 
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3.1.5.3 Rac1 is crucially involved in ANP-induced ROS generation and MKP-1 expression 
We then wanted to clarify whether the ANP-induced activation of Rac1 is causally related to the 
increase of ROS formation by ANP. Therefore, we transfected HMEC (due to difficulties with the 
transfection of plasmids into primary HUVEC)89 with different Rac1 mutants: the dominant-negative 
RacN17 and the constitutively active RacV12 mutant. RacN17 clearly abrogated the fluorescence 
signal induced by ANP, whereas RacV12 mimicked the ANP-induced increase of ROS generation 
(figure 37, lower panel). The upregulation of MKP-1 protein by ANP was completely abolished by 
RacN17, whereas RacV12 mimicked the effect of ANP on MKP-1 expression (figure 37, upper panel). 
These data clearly point to a crucial involvement of Rac1 in both ANP-induced ROS generation and 
MKP-1 expression. 
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Figure 37:  Influence of Rac1 mutants on ANP-induced ROS generation and MKP-1 expression. HMEC were 
transfected with the empty control plasmid pcDNA3.1, the dominant-negative (RacN17), or the constitutively 
active (RacV12) Rac1 mutant as described in section 2.8.1. Cells were treated with ANP 1 µM. ROS 
generation was measured as described in section 2.5. MKP-1 protein expression (60 min ANP) was 
determined as described in section 2.3.3. * P  ≤ 0.05 vs. pcDNA3.1 alone. † P ≤ 0.05 vs. ANP+pcDNA3.1. 
 
3.1.6 MKP-1 induction is not mediated by PKC, ERK, or p38 MAPK 
Protein kinase C (PKC) and the MAP kinases ERK, p38, and JNK have been communicated to 
meditate the induction of MKP-1 after diverse stimuli. Since we intended to investigate which kinase is 
involved in the ANP-induced upregulation of MKP-1, we treated HUVEC with well-established 
pharmacological inhibitors of these kinases. The inhibitors calphostin C for PKC (figure 38A), 
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PD98059 for the ERK pathway (figure 38B), and SB203580 for p38 MAPK (figure 38C) did not affect 
ANP-induced MKP-1 protein expression, suggesting that PKC, ERK, and p38 MAPK do not mediate 
the induction of MKP-1 by ANP. 
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Figure 38: MKP-1 induction by ANP is not mediated by PKC, ERK, or p38 MAPK. HUVEC were either left untreated or 
were pre-treated with (A) the protein kinase C (PKC) inhibitor calphostin C (CC, 100 nM, 60 min), (B) the 
ERK pathway inhibitor PD98059 (PD, 10 µM, 60 min), or (C) the p38 MAPK inhibitor SB203580 (SB, 5 µM, 
60 min). ANP was added to the cells for 60 min. MKP-1 protein expression was determined by Western blot 
analysis as described in section 2.3.3. 
 
3.1.7 Role of JNK and AP-1 
3.1.7.1 JNK mediates the induction of MKP-1 by ANP 
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Figure 39: JNK mediated the induction of MKP-1 by ANP. A: HUVEC were either left untreated or were pre-treated with 
the JNK inhibitor SP600125 (SP, 10 µM, 60 min). ANP was added to the cells for 60 min. MKP-1 protein 
expression was determined by Western blot analysis as described in section 2.3.3. B: HUVEC were either 
left untreated or were pre-treated with SP (10 µM, 60 min). ANP was added for 30 min. MKP-1 and GAPDH 
mRNA expression was determined by RT-PCR and subsequent agarose gel electrophoresis as described in 
section 2.4. 
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The JNK inhibitor SP600125 abolished the ANP-induced expression of both MKP-1 protein (figure 
39A) and mRNA expression (figure 39B) in HUVEC, suggesting a crucial involvement of JNK in the 
upregulation of MKP-1 by ANP. 
 
3.1.7.2 ANP rapidly activates JNK 
Since we found that JNK (p46/p54) is crucial for the induction of MKP-1 by ANP, the question arose 
whether ANP is in fact able to activate JNK. We revealed that ANP rapidly increases the activated 
form of JNK (phospho-p46/p54) with a maximum at about 5 min (figure 40, upper panel). 
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Figure 40: ANP rapidly activates JNK. HUVEC were either left untreated (Co) or were treated with ANP (1 µM) for the 
indicated times. The amount of phospho-JNK (p-p46/54, upper panel) and total JNK (p46/54, lower panel, 
showing uniformity of total JNK content) was determined by Western blot analysis as described in section 
2.3.3. 
 
3.1.7.3 Superoxide is involved in the activation of JNK by ANP 
Since we found that ANP induces the intracellular formation of superoxide, we investigated the role of 
superoxide in the activation of JNK by ANP. HUVEC were treated with the superoxide scavengers 
tiron and PEG-SOD. Figure 41 shows that both tiron (figure 41A) and PEG-SOD (figure 41B) 
decreased ANP-induced JNK phosphorylation. This indicates that superoxide is crucial for the 
activation of JNK by ANP. 
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Figure 41: Superoxide is involved in the activation of JNK by ANP. HUVEC were either left untreated or were pre-
treated with the superoxide scavengers (A) tiron (Ti, 10 mM, 60 min) or (B) PEG-SOD (300 U/ml, 60 min). 
ANP (1 µM) was added to the cells for 5 min. The amount of phospho-JNK (upper panels) and total JNK 
(lower panels, showing uniformity of total JNK content) was determined by Western blot analysis as 
described in section 2.3.3. 
 
3.1.7.4 ANP activates AP-1 via JNK 
The transcription factor activator protein-1 (AP-1) is an important target of JNK. Therefore, we 
assessed DNA-binding of AP-1 after treatment of HUVEC with ANP and the JNK inhibitor SP600125. 
The inhibition of JNK completely blocked the ANP-induced activity of AP-1 (figure 42). 
 
Co         ANP        SP    ANP+SP
15      30              15      30   min
AP-1
DNA complex
free probe  
Figure 42: ANP activates AP-1 via JNK. HUVEC were either left untreated (Co) or were pre-treated with the JNK 
inhibitor SP600125 (10 µM, 60 min). ANP (1 µM) was added to the cells for the indicated times. AP-1 DNA-
binding activity was determined by electrophoretic mobility shift assay (EMSA) as described in section 2.7. 
 
3.1.7.5 AP-1 is crucially involved in the upregulation of MKP-1 by ANP 
To causally link AP-1 to the induction of MKP-1, we used a well-established AP-1 decoy approach. 
The functionality of this approach, i.e. ability of the decoys to inhibit the activation of AP-1 by ANP, is 
demonstrated in figure 43. 
Results 59 
scr decoy
AP-1
DNA complex
free probe
0 15 30      0    15    30       min ANP
 
Figure 43: Prove of functionality of the used AP-1 decoy. HUVEC were transfected with AP-1 decoy or scrambled 
decoy (scr) as described in section 2.8.3. Cells were treated with ANP (1 µM) for the indicated times. DNA-
binding activity of AP-1 was determined by electrophoretic mobility shift assay (EMSA) as described in 
section 2.7. 
 
HUVEC were transfected with the AP-1 decoy and treated with ANP. The decoy completely abrogated 
the increase of MKP-1 expression by ANP (figure 44), suggesting that AP-1 is crucial for the ANP-
induced upregulation of MKP-1. 
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Figure 44: AP-1 is crucially involved in the upregulation of MKP-1 by ANP. HUVEC were transfected with AP-1 decoy 
or scrambled decoy (scr) as described in section 2.8.3. Cells were treated with ANP (1 µM) for 60 min. 
MKP-1 protein expression was determined by Western blot analysis as described in section 2.3.3. 
 
3.1.8 ROS generation in intact blood vessels 
We aimed to clarify whether the ANP-induced ROS generation measured in cultured endothelial cells 
is also relevant in vivo, i.e. in intact blood vessels. Therefore, we loaded rat lung endothelial cells in 
isolated perfused organs with an ROS-sensitive fluorescent dye. Intracellular ROS generation was 
measured by in situ fluorescence microscopy. Resting endothelial cells showed no alteration of dye 
fluorescence over 2 h (figure 45A), but ANP-treatment increased endothelial ROS formation (figure 
45B). This increase was abolished by addition of the Nox inhibitor DPI (figure 45C, figure 46). 
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Figure 45: ROS generation in the endothelium of intact blood vessels. Baseline fluorescence is shown in each panel. 
A: Regular HEPES buffer was continuously infused over 120 min. B: ANP (1 µM) was infused for 60 min, 
followed by 60 min of buffer perfusion. C: Vessels were pre-treated with the Nox inhibitor 
diphenyleneiodonium (DPI, 20 µM) for 20 min, followed by 60 min ANP and 60 min buffer perfusion. One 
representative graph and image out of 5 independent experiments is shown. ROS generation in the 
endothelium of isolated-perfused rat lungs was determined as described in section 2.6. 
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Figure 46: ROS generation in the endothelium of intact blood vessels. Data of ANP-treated versus ANP- and DPI-
treated cells of all 5 experiments are shown as means ± SEM. * P ≤ 0.05 vs. data from lungs treated with 
ANP alone. ROS generation in the endothelium of isolated-perfused rat lung vessels was determined as 
described in section 2.6. 
 
Moreover, we aimed to check whether ANP is able to increase MKP-1 not only in cultured endothelial 
cells, but also in the rat lung. Importantly, as shown in figure 47, ANP induces MKP-1 protein 
expression also in vivo. 
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Figure 47: ANP induces MKP-1 in the endothelium of intact blood vessels. Rats were anesthetized and a NaCl-solution 
(Co) or ANP (approx. 1 µM plasma concentration) was parenterally applied. After 1 h, lungs were excised. 
Rat lung lysates were investigated for MKP-1 protein expression by Western blot analysis as described in 
section 2.3.2. 
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3.2 Dexamethasone and MKP-1 
3.2.1 Dex reduces TNF-α-induced E-selectin expression 
Dex is known to reduce TNF-α-induced E-selectin expression in endothelial cells. We aimed to 
confirm this fact in our cell system. Pre-treating HUVEC with Dex concentration-dependently reduced 
the expression of E-selectin (figure 48). Importantly, we found that even low concentrations of Dex (1-
100 nM) lead to a highly significant reduction of E-selectin expression. 
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Figure 48: Dex reduces TNF-α-induced E-selectin expression. HUVEC were either left untreated (Co) or were pre-
treated with dexamethasone (Dex, 60 min, concentrations as indicated). Where indicated, cells were treated 
with TNF-α (10 nag/ml) for 4 h. E-selectin expression was analyzed by flow cytometry as described in 
section 2.11. *** P  ≤ 0.001 vs. Co. + P ≤ 0.05 vs. TNF. +++ P ≤ 0.001 vs. TNF. 
 
3.2.2 Dex at low concentrations does not influence NF-κB 
The transcription factor NF-κB is thought to play a key role in the upregulation of E-selectin upon 
TNF-α treatment and Dex is known to inhibit NF-κB. Interestingly, we found that in our system TNF-α-
activated NF-κB is not influenced by Dex at low concentrations. Figure 49 shows that Dex neither 
alters the TNF-α-induced increase of NF-κB DNA-binding activity (figure 49B) nor the TNF-α-induced 
p65 translocation (figure 49A). To ensure the functionality of our EMSA system, we used the well-
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established NF-κB inhibitors pyrrolidine dithiocarbamate (PDTC) and parthenolide. Both were able to 
abolish the TNF-α-induced NF-κB DNA-binding activity. 
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Figure 49: Dex at low concentrations does not influence NF-κB. A: HUVEC were left untreated (Co) or were pre-
treated with Dex for 60 min (concentrations as indicated). TNF-α (10 ng/ml) was added for 60 min. 
Immunocytochemistry and confocal microscopy were performed as described in section 2.10. B: HUVEC 
were left untreated (Co) or were pre-treated with Dex for 60 min (concentrations as indicated). The NF-κB 
inhibitors PDTC (50 µM, 60 min) and parthenolide (parth, 5 µM, 60 min) served as positive control. TNF-α 
(10 ng/ml) was added for 60 min. NF-κB DNA-binding activity was judged by electrophoretic mobility shift 
assay (EMSA) as described in section 2.7. 
 
3.2.3 p38 MAPK is involved in TNF-α-induced E-selectin expression 
Since we revealed that Dex at low concentrations does not influence NF-κB, we checked whether p38 
MAPK could be involved in the inhibitory action on E-selectin. Inhibition of p38 MAPK by a 
pharmacological inhibitor (SB203580) resulted in a strong decrease of TNF-α-evoked E-selectin 
expression (figure 50) pointing to a crucial involvement of p38 MAPK in E-selectin expression induced 
by TNF-α. 
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Figure 50: p38 MAPK is involved in E-selectin expression induced by TNF-α. HUVEC were either left untreated (Co) or 
were pre-treated with SB203580 (SB, 10 µM, 60 min). TNF-α (10 ng/ml) was added for 4 h. E-selectin 
expression was analyzed by flow cytometry as described in section 2.11. *** P  ≤ 0.001 vs. Co. +++ P ≤ 0.001 
vs. TNF. 
 
3.2.4 Influence of Dex on TNF-α-activated p38 MAPK 
Since we could show that p38 MAPK is crucially involved in TNF-α-induced E-selectin expression, we 
wanted to clarify whether p38 MAPK activity is influenced by Dex at a low concentration (1 nM). First, 
we performed a TNF-α time course and found a very rapid (within 5 min) and transient activation of 
p38 MAPK (figure 51). 
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Figure 51: TNF-α time-dependently activates p38 MAPK. HUVEC were either left untreated (Co) or were treated with 
TNF-α (10 ng/ml) for the indicated times. Amounts of phospho-p38 MAPK (p-p38) and p38 MAPK were 
judged by Western blot analysis as described in section 2.3.3. 
 
We then checked whether pre-incubation of HUVEC with Dex (1 nM) alters the activation status of p38 
MAPK and revealed that Dex abrogates the activation of p38 MAPK by TNF-α (figure 52). 
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Figure 52: Dex abrogates TNF-α-induced p38 MAPK activation. HUVEC were either left untreated (Co) or were pre-
treated with Dex (60 min, 1 nM). TNF-α (10 ng/ml) was added for the indicated times. Amounts of phospho-
p38 MAPK (p-p38) and p38 MAPK were judged by Western blot analysis as described in section 2.3.3. 
 
3.2.5 Vanadate abrogates the influence of Dex on p38 MAPK 
We wanted to clarify the underlying mechanism of p38 MAPK deactivation. We assumed an 
involvement of phosphatases, which could be activated or induced by Dex. Therefore, we treated 
HUVEC with sodium orthovanadate, a known inhibitor of protein tyrosine phosphatases. As shown in 
figure 53, we found that sodium orthovanadate strongly diminished the influence of Dex on TNF-α-
induced p38 MAPK activation. These results suggested that protein tyrosine phosphatases are 
involved in the deactivation of p38 MAPK by Dex. 
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Figure 53: Vanadate abrogates the influence of Dex on p38 MAPK activation induced by TNF-α. HUVEC were either 
left untreated (Co) or were pre-treated with the protein tyrosine phosphatase inhibitor sodium orthovanadate 
(VO4, 100 µM, 30 min). Cells were treated with Dex (1 nM) for 60 min. TNF-α (10 ng/ml) was added for 15 
min. Amounts of phospho-p38 MAPK (p-p38) and p38 MAPK were judged by Western blot analysis as 
described in section 2.3.3. 
 
3.2.6 MKP-1 induction by Dex 
Since tyrosine phosphatases seem to be involved in the deactivation of p38 MAPK by Dex, we 
checked whether MKP-1 is upregulated by Dex. In fact, treatment of HUVEC with different Dex 
concentrations lead to an increased expression of MKP-1 protein (figure 54A). A maximal MKP-1 
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induction occurred at 1 nM Dex. The upregulation was found to be time-dependent with a maximum at 
60 min (figure 54B). 
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Figure 54: Dex induces MKP-1 in endothelial cells. A: HUVEC were either left untreated (Co) or were treated with Dex 
(60 min) at the indicated concentrations. B: HUVEC were either left untreated (Co) or were treated with Dex 
(1 nM) for the indicated times. MKP-1 protein expression was determined by Western blot analysis as 
described in section 2.3.3. 
 
3.2.7 Dex induces MKP-1 via glucocorticoid receptor 
We wanted to investigate whether the observed upregulation of MKP-1 depends on the activation of 
the glucocorticoid receptor (GR). Therefore, we used the well-established GR antagonist 
RU486/mifepristone. Figure 55 shows that RU486 completely blocks the induction of MKP-1 protein by 
Dex pointing to a crucial involvement of the glucocorticoid receptor. 
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Figure 55: Dex induces MKP-1 via the glucocorticoid receptor. HUVEC were either left untreated (Co) or were pre-
treated with the glucocorticoid receptor antagonist RU486/mifepristone (RU, 10 nM, 15 min). Dex (1 nM) 
was added for 60 min. MKP-1 protein expression was determined by Western blot analysis as described in 
section 2.3.3. 
 
3.2.8 MKP-1 antisense restores p38 MAPK activation 
We aimed to clarify whether MKP-1 in fact plays a causal role in the reduction of TNF-α-induced p38 
MAPK activation. Therefore, we used an MKP-1 antisense approach. First, we checked the 
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functionality of the MKP-1 antisense oligonucleotides. As shown in figure 56, transfection of HUVEC 
with MKP-1 antisense but not sense strongly diminished the Dex-induced increase of MKP-1 protein. 
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Figure 56: Functionality of MKP-1 antisense oligonucleotides. HUVEC were either left untreated (Co) or were treated 
with Dex (1 nM) for 60 min in the presence of MKP-1 sense or antisense oligonucleotides (4 h). The 
transfection with the oligonucleotides was performed as described in section 2.8.2. MKP-1 protein 
expression was determined by Western blot analysis as described in section 2.3.3. 
 
After confirming the functionality of our antisense approach, we treated HUVEC with Dex and TNF-α 
in the presence of MKP-1 antisense and found that the capability of Dex to diminish the TNF-α-
induced activation of p38 MAPK was completely reversed (figure 57). This result shows that MKP-1 is 
crucially involved in the deactivation of p38 MAPK by Dex. 
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Figure 57: MKP-1 antisense reverses the ability of Dex to diminish the TNF-α-induced p38 MAPK activation. HUVEC 
were either left untreated (Co) or were pre-treated with Dex (1 nM) for 60 min in the presence of MKP-1 
sense or antisense oligonucleotides (4 h). TNF-α (10 ng/ml) was added for 15 min. The transfection with the 
oligonucleotides was performed as described in section 2.8.2. Amounts of phospho-p38 MAPK (p-p38) and 
p38 MAPK were judged by Western blot analysis as described in section 2.3.3. 
 
3.2.9 MKP-1 antisense restores E-selectin expression 
Furthermore, we wanted to causally relate the Dex-induced increase of MKP-1 to the reduction of 
TNF-α-induced E-selectin expression. We again used MKP-1 antisense oligonucleotides and found 
that the reduction of E-selectin expression by Dex was significantly reversed in the presence of MKP-1 
antisense oligonucleotides (figure 58), pointing to a crucial involvement of MKP-1 in the pathway by 
which Dex diminishes TNF-α-induced E-selectin expression. 
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Figure 58: MKP-1 antisense restores E-selectin expression. HUVEC were either left untreated (Co) or were pre-treated 
with Dex (1 nM) for 60 min in the presence of MKP-1 sense or antisense oligonucleotides (4 h). TNF-α (10 
ng/ml) was added for 4 h. The transfection with the oligonucleotides was performed as described in section 
2.8.2. E-selectin expression was analyzed by flow cytometry as described in section 2.11. *** P  ≤ 0.001 vs. 
Co (sense). ++ P ≤ 0.01 vs. Dex+TNF (sense). ### P ≤ 0.001 vs. TNF (sense). 
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4.1 ANP and MKP-1 
4.1.1 Beneficial actions of MKP-1 
In the recent years the MAPK phosphatase MKP-1 emerged as an important mediator of beneficial 
actions in cardiovascular and renal diseases. These properties were demonstrated in diverse cell 
culture and in vivo models: 
 
(i) MKP-1 seems to play an important role in the proliferation of vascular smooth muscle cells 
(VSMCs). The uncontrolled growth of VSMCs is commonly regarded as a key event in the 
pathogenesis of different vascular disorders, such as atherosclerosis. Li et al. revealed that 
overexpression of MKP-1 in VSMCs leads to an inhibition of DNA-synthesis, i.e. an attenuated VSMC 
proliferation.90 Jacob et al. showed that the inhibiting effect of insulin on platelet-derived growth factor 
(PDGF)-evoked VSMC migration is mediated via NO/cGMP-induced MKP-1.91 A defective induction of 
MKP-1 in spontaneous hypertensive rats was found to promote the proliferation and hypertrophy of 
VSMCs.92 Moreover, a disturbed MKP-1 expression in these rats was revealed to be due to defects of 
the NO/cGMP signaling pathway.93 In diabetic rats, an enhanced VSMC migration was shown to be 
crucially related to a failure of insulin-stimulated MKP-1 expression.94 
 
(ii) The induction of MKP-1 protects against cardiac dysfunctions. Cardiomyocyte hypertrophy, i.e. an 
increased ventricular mass, is a risk factor for cardiac morbidity and mortality. The ANP-induced 
inhibition of cardiomyocyte hypertrophy evoked by angiotensin II or endothelin-1 was found to be 
mediated via an increased MKP-1 expression.95 Moreover, a recent study communicated that mice 
overexpressing MKP-1 are protected against cardiac ischemia-reperfusion injury, while MKP-1 gene-
targeted mice showed greater injury.96 
 
(iii) MKP-1 has been reported to mediate cytoprotective effects in renal cells. Tubular hypertrophy is 
an early morphological feature of chronic renal diseases. In this context, ANP was shown to reduce 
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angiotensin II-evoked hypertrophy of renal tubular cells via an induction of MKP-1.27 In mechanical 
strain-activated glomerular mesangial cells, an increased MKP-1 induction by estradiol was found to 
reduce the activity of MAPKs. MKP-1 induction by estradiol was assumed to be the cause for the 
protective effect of female gender on renal disease progression.97 
 
Taken together, these data clearly point to a pivotal role for MKP-1 in different signaling pathways 
transducing anti-atherogenic and cytoprotective actions. 
4.1.2 ANP induces MKP-1 
In accordance with the above described cytoprotective potential of MKP-1, we have recently found 
that ANP exerts its beneficial actions on TNF-α-activated endothelial cells via an induction of 
MKP-1.14,15 Therefore, it seemed of special interest to clarify the underlying signaling pathway leading 
to an upregulation of MKP-1 by ANP since mechanisms involved in MKP-1 induction by ANP in 
endothelial cells have as yet been completely unknown. As previously shown by ourselves,14 a rapid 
expression of MKP-1 occurs upon treatment of HUVEC with ANP. MKP-1 is an immediate early gene 
product and therefore well known to be rapidly expressed (for review see98). ANP has as yet been 
described to induce MKP-1 in the tubular27 and glomerular mesangial cells99, and in cardiomyocytes95. 
 
The induction of MKP-1 in HUVEC was found to depend on the NPR-A/cGMP-pathway, whereas an 
involvement of NPR-C was excluded. Supporting this result, a cGMP-dependent MKP-1 upregulation 
was described in VSMC91,93 and renal cells.27,99 Data regarding the mechanism of cGMP-mediated 
MKP-1 induction, however, have as yet been lacking. 
 
Blockade of protein biosynthesis did not inhibit the early increase of MKP-1 at 15 min, suggesting that 
other effects than an increase of MKP-1 protein de novo synthesis are responsible for this early 
induction. MKP-1 is known to be rapidly degraded by the ubiquitin/proteasome-pathway.25 It might be 
speculated that ANP interferes with MKP-1 catabolism accounting for the early increase of MKP-1. 
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The augmented MKP-1 protein levels at later time points, however, definitely represent newly 
synthesized protein. 
 
Treatment of HUVEC with ANP leads to an increase of intracellular cGMP via activation of NPR-A 
(data not shown). Since we have shown that MKP-1 induction by ANP is mediated by the NPR-
A/cGMP-pathway, we aimed to elucidate an involvement of protein kinase G I (PKG I), an important 
cGMP effector system. Controversial data exist regarding the presence of PKG I in endothelial cells. 
MacMillan-Crow et al. were the first who described the presence of PKG I in primary bovine 
endothelial cells.100 By using inhibitors and activators of PKG I, two groups found an involvement of 
PKG I in the ANP-induced proliferation of HUVEC.101,102 In contrast, the group of van Hinsbergh 
showed that PKG I is absent in endothelial cells derived from umbilical veins.103 Our data confirm the 
latter: PKG I is not expressed in HUVEC and, therefore, not involved as an cGMP effector system.  
Consistently, our group also observed that the cGMP-mediated induction of heme oxygenase-1 by 
ANP in HUVEC was not influenced by an inhibitor of PKG I104. The controversy about an involvement 
of PKG I in cGMP-mediated signaling pathways might be explained by the findings that the expression 
of PKG in endothelial cells might depend on their origin and that PKG I might be down-regulated 
during cell culture passaging.105 However, we have found that PKG I is not even expressed in primary 
HUVECs. 
4.1.3 Generation of ROS by ANP 
Exogenously supplied hydrogen peroxide (H2O2) led to augmented endothelial MKP-1 protein levels. 
This is in line with two studies showing that H2O2 is able to upregulate MKP-1 expression in epithelial28 
and smooth muscle cells.106 This potency of exogenous ROS to induce MKP raised the question 
whether ANP possesses the ability to increase endothelial ROS generation. ANP has been shown to 
induce the production of ROS in macrophages107 and in renal cells,27 but nothing has as yet been 
reported about its potency to induce ROS in the endothelium. We for the first time provide evidence 
that ANP concentration-dependently augments the formation of ROS. In analogy to the induction of 
MKP-1, this increase was shown to be mediated via NPR-A/cGMP, which is in consistence with a 
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recent study reporting that cGMP is able to induce ROS in cardiomyocytes.108 Importantly, we could 
establish a causal link between ROS generation in EC and MKP-1 induction by using several 
antioxidants. 
 
It seemed of special interest to clarify whether these results obtained from cell culture experiments 
could be confirmed in vivo, i.e. by in situ measurement of ROS in the endothelium of lung vessels. In 
fact, we provide clear evidence that ANP induces endothelial ROS generation in intact vessels. Similar 
to our cell culture model, we confirmed that ANP induces MKP-1 also in the isolated perfused rat lung. 
This strongly suggests an in vivo relevance of our findings obtained from cultured endothelial cells. 
 
Reactive oxidants in the pulmonary vascular wall are mainly mentioned in the context of 
pathophysiological events,109 but also appear as signaling molecules.48 Studies concerning a 
connection between ANP and ROS formation in the lung are as yet not available. ANP has been 
shown to reduce a TNF-α-evoked increase of endothelial permeability14 and ANP-induced pulmonary 
ROS generation was found to be connected to ANP’s ability to counteract a thrombin- and oxidant-
induced increase in permeability of pulmonary endothelial cells.110,111 Therefore, it might be speculated 
that an ANP-evoked ROS augmentation in pulmonary ECs could contribute to ANP’s protective effect. 
This important issue needs to be examined in detail in future studies. 
 
Summarizing, we have shown that ANP enhances ROS production in endothelial cells both in cell 
culture as well as in intact blood vessels. ROS emerged as a critical signaling step in ANP-induced 
MKP-1 induction.  
4.1.4 Involvement of NAD(P)H oxidase 
A great variety of sources involved in endothelial ROS generation exists including the mitochondrial 
respiratory chain, and peroxisomal, cytosolic, and membrane-bound oxidases.48 In the recent years 
the superoxide-producing NAD(P)H oxidase (Nox) enzyme complex has emerged as the major source 
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of ROS in the endothelium.57 Importantly, we identified Nox as the crucial ANP-induced ROS source 
responsible for MKP-1 induction by using different inhibitors. 
 
Experiments with catalase and superoxide dismutase (SOD) corroborated that superoxide, but not 
H2O2, is the crucially involved oxidant species mediating the effects of ANP. SOD converts superoxide 
to H2O2. Interestingly, we did not observe an augmented MKP-1 induction upon ANP/SOD-treatment, 
although exogenously supplied H2O2 leads to an upregulation of MKP-1. This might be due to the fact 
that endothelial Nox produces only low amounts of superoxide, which may consequently lead to SOD-
converted H2O2 levels unable to increase MKP-1 expression. In contrast, the exogenously supplied 
amounts of hydrogen peroxide are incomparably higher. 
 
The phagocyte-type NAD(P)H oxidase contains a transmembrane electron transport chain. Oxygen is 
reduced to superoxide in the extracellular space or in phagocytic vacuoles.112 However, neither the 
precise structure nor the exact localization of functionally active endothelial NAD(P)H oxidase have as 
yet been clarified. The question arises whether endothelial Nox releases superoxide intra- or 
extracellularly. Our data suggest an intracellular superoxide release, since the cell-permeable PEG-
SOD completely blocked the fluorescence signal, whereas SOD present only extracellularly did not 
alter the signal. 
 
In order to clarify which Nox isoform is responsible for superoxide generation, we characterized the 
Nox homologue spectrum expressed in HUVEC and HMEC and found Nox2 and Nox4 mRNA and 
protein to be present. Ago et al. communicated similar findings for HUVEC and rat aortic endothelial 
cells,62 but they also described an extremely low expression of Nox1, which we could not confirm and 
which might be due to different cell culture conditions and experimental settings. We used a well-
established Nox2/4 antisense approach62,113 and found that only Nox2 is responsible for the ANP-
induced superoxide generation and subsequent MKP-1 induction. Interestingly, the two Nox inhibitors 
DPI and gp91ds-tat both reduced superoxide production below control levels. This suggests a 
constitutive production of superoxide in resting cells. DPI is known to inhibit several other ROS 
sources (flavin-containing enzymes), which could in part account for basal ROS/superoxide 
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production. The fact that the inhibitor peptide gp91ds-tat targets both Nox2 and Nox4 suggests that 
Nox4 might be a constitutively active Nox isoform responsible for basal levels of superoxide formation, 
since Nox2 but not Nox4 antisense reverses the effect of ANP. In summary, we found that ANP-
induced superoxide generation and MKP-1 expression are mediated via a Nox2-containing NAD(P)H 
oxidase. 
4.1.5 The role of Rac1 
Rac1, a well-known activating component of the phagocyte-type NAD(P)H oxidase, was revealed to 
be rapidly activated by ANP. The precise role of Rac1 in endothelial Nox assembly and activation is as 
yet not completely understood and only few studies suggest a role for Rac1 in Nox-derived endothelial 
ROS generation.114-116 Therefore, it might be of special interest that our results show for the first time 
that Rac1 plays a pivotal role both in the generation of superoxide as well as in the upregulation of 
MKP-1. We observed that Rac1 translocates to the plasma membrane, which represents another 
indicator for its activation.65 Whether endothelial Nox assembles at the membrane, as it does in 
phagocytes, as well as the question about the direction of superoxide release (cytosolic vs. 
extracellular), however, remains to be clarified. 
 
A number of studies report that an activation of Rac1 and a subsequent superoxide formation is 
connected to different pro-inflammatory effects in the endothelium. For instance, Rac1 and superoxide 
were shown to regulate the expression of different endothelial cellular adhesion molecules (CAMs).117 
Besides the upregulation of CAMs as a typical marker of endothelial cell activation, also the 
expression and release of monocyte chemoattractant protein-1 (MCP-1) has recently been revealed to 
be mediated via Rac1 and superoxide.118 In this context, it is worth mentioning that in our system the 
activation of Rac1 by ANP exerts cytoprotective effects due to the upregulation of MKP-1. Our findings 
are supported by a study showing that Rac1-dependent generation of ROS leads to a protection of 
HUVEC against TNF-α-induced cell death.119 It seems that Rac1 possesses the ability to participate in 
divergent signaling pathways mediating either pro- or anti-inflammatory effects. Further studies are 
required to investigate the mechanistic basis for this variable role of Rac1 in different settings. 
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4.1.6 Involvement of the JNK/AP-1 pathway 
The downstream signaling of MKP-1, i.e. the control of MAPK activity, is quite well investigated 
compared to the upstream pathways leading to an induction of MKP-1. Referring to the latter, we 
aimed to elucidate the role of different protein kinases, which could potentially be involved in the 
induction of MKP-1 (PKC, ERK, JNK, and p38 MAPK).29-32 The data from the literature suggest that 
the signaling pathway responsible for an induction of MKP-1 highly depends on both the used stimulus 
and the cell-type. By using well-established pharmacological inhibitors, we could causally link JNK to 
the ANP-induced expression of MKP-1 in HUVEC. A role for PKC, ERK, and p38 MAPK was 
excluded. Accordingly, we investigated the influence of ANP on JNK activation and found a rapid and 
transient activation of JNK with a maximum at about 5 min. ANP is also known to induce JNK activity 
at later time points, suggesting a biphasic process evoked by ANP.104 Since ANP induces MKP-1 
protein biosynthesis within 30 min, the very rapid JNK activation by ANP supports the crucial role for 
JNK in MKP-1 induction. Taken together, we revealed for the first time that ANP-induced MKP-1 
protein expression in the endothelium is mediated via JNK, but excluded a role for PKC, ERK, or p38 
MAPK. 
 
The transcription factor AP-1 is a central target of JNK and the promoter of MKP-1 possesses an AP-1 
binding domain.120 Therefore, a role for AP-1 in mediating the signal from activated JNK to MKP-1 
expression seemed plausible. As previously shown by ourselves104 and confirmed in the present 
study, ANP is able to induce AP-1 activity. A study showing cGMP, the second messenger of ANP, as 
inducer of AP-1 activity121 supports our finding of ANP as an activator of AP-1. Considering that ANP 
activates JNK within 2 min and that MKP-1 de novo protein synthesis starts at about 30 min, the 
activation of AP-1 within 15 min could be responsible for the induction of MKP-1. In fact, we proved 
the crucial involvement of AP-1 in the signaling pathway leading to an upregulation of MKP-1 by using 
an AP-1 decoy approach.122 
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Since numerous studies demonstrate that JNK is regulated by ROS,45,123 we checked for a 
participation of superoxide in its activation. In fact, we were able to causally link the ANP-induced 
formation of superoxide to the activation of JNK by using different superoxide scavengers. 
 
In conclusion, our data suggest that JNK, activated by superoxide, mediates the activation of AP-1. 
JNK and AP-1 are crucially involved in the induction of MKP-1 by ANP. 
4.1.7 General comments 
The potential of ANP to induce an increase in ROS formation might be regarded as a form of 
preconditioning leading to a protection of endothelial cells against an inflammatory response, since 
ANP induces MKP-1, the crucial mediator of ANP’s cytoprotective effects on the endothelium.14,15 This 
consideration is supported by a similar observation in HUVEC, which were treated for a short time with 
hydrogen peroxide: the cells showed a strongly reduced inflammatory response124 upon activation by 
TNF-α. 
 
A huge number of studies suggest that activation of Nox leads to oxidant stress, which is thought to be 
involved in the pathogenesis of many cardiovascular diseases, such as hypertension, atherosclerosis, 
diabetes, or heart failure.125 The activity of NAD(P)H oxidase is regulated by cytokines, growth factors, 
and mechanical forces. Endothelial dysfunction caused by the inactivation of nitric oxide (NO) by Nox-
derived superoxide seems to play an important role in the above mentioned disorders.125 Moreover, 
Nox activators like thrombin, angiotensin II, or TNF-α55 are typically pro-inflammatory agents. 
Therefore, it seems of special interest that the functional outcome of Nox activation by ANP is the 
induction of MKP-1, a protein which exerts profound cytoprotective effects on endothelial cells.14,15 
This is in consistence with a growing number of studies showing that ROS are not only deleterious 
molecules involved in a plethora of pathologies, but also important physiological signal transducers.126 
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4.2 Dexamethasone and MKP-1 
4.2.1 Dex reduces E-selectin expression independent of NF-κB 
Dex is well-known to decrease LPS-, IL-1-, and TNF-α-induced endothelial E-selectin expression.127-
131 We confirmed this in our experimental setting and, importantly, found that even low Dex 
concentrations (1-100 nM) lead to a significant reduction of E-selection induced by TNF-α. It is 
commonly accepted that the upregulation of E-selectin in activated endothelial cells is an NF-κB-
regulated event132 and that Dex interferes with the NF-κB-pathway.68 This interference is thought to be 
one of the major mechanisms of action of Dex responsible for its anti-inflammatory properties. 
Therefore, it was very interesting to find that Dex at low concentrations (1-100 nM) readily decreases 
TNF-α-evoked E-selectin expression, whereas it does not influence TNF-α-activated NF-κB. Higher 
Dex concentrations (≥ 1,000 nM) lead to a decrease of NF-κB activity. The finding that Dex exerts a 
concentration-dependent influence on the activity of NF-κB is supported by studies performed in 
human lung epithelial cells,129 human peripheral blood mononuclear cells,133 human astrocytoma and 
neuroblastoma cells,134 and fibroblast-like rheumatoid synoviocytes.135 However, to the best of our 
knowledge, this effect has as yet been unknown for endothelial cells. 
4.2.2 The role of p38 MAPK in TNF-α-induced E-selectin expression 
Besides the well-known NF-κB-dependent upregulation of E-selectin by TNF-α, an additional pathway 
has been described that occurs simultaneously with the NF-κB-pathway: TNF-α activates both p38 
MAPK and JNK, resulting in the phosphorylation of the transcription factors activating transcription 
factor-2 (ATF-2) and c-Jun, respectively. The NF-κB- and the ATF-2/c-Jun-pathway converge on the 
E-selectin promoter. Both pathways are required for full activation of E-selectin gene transcription in 
response to TNF-α.136 Moreover, a study by Reimold et al. stressed the importance of an ATF-2 
activation for E-selectin expression since ATF-2-deficient mice showed an attenuated E-selectin 
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expression.137 This highlights the important role of p38 MAPK in the upregulation of E-selectin by TNF-
α. In accordance with these findings, we found that a pharmacological inhibitor of p38 MAPK activity 
was able to significantly decrease E-selectin expression (50% reduction) in HUVEC. 
4.2.3 Dex reduces p38 MAPK activity via induction of MKP-1 
In the recent years an influence of glucocorticoids on different members of the MAPK family has been 
increasingly recognized as a mechanism involved in glucocorticoid action.73 In this context, a study by 
Pelaia et al. reported that Dex (100 nM) is very effective in preventing the TNF-α-induced activation of 
p38 MAPK in human pulmonary endothelial cells.138 This is in consistence with our finding that pre-
treatment of Dex abrogates TNF-α-induced p38 MAPK activity in primary human endothelial cells 
derived from umbilical veins. The question arose how Dex is able to decrease the activity of p38 
MAPK. We hypothesized that a phosphatase accounts for this decrease. In fact, a phosphatase 
inhibitor reversed the effect of Dex on p38 MAPK. MKP-1 has been shown by ourselves to be crucially 
involved in the deactivation of TNF-α-induced p38 MAPK in endothelial cells.14,15 Additionally, Lasa et 
al. reported that MKP-1 is the only p38 MAPK-inhibiting phosphatase induced by Dex in epithelial 
cells.139 Therefore, we hypothesized an induction of MKP-1 by Dex in HUVEC and, in fact, found a 
time- and concentration-dependent upregulation of MKP-1. MKP-1 expression is known to be induced 
by Dex in mast cells,140,141 epithelial cells,139,142 macrophages,143 osteoblasts,144 adipocytes,145 and 
breast cancer cells.146 However, nothing has as yet been reported about the ability of Dex to increase 
MKP-1 protein levels in human endothelial cells. It has to be mentioned that in most studies Dex is 
used at concentrations of about 100 nM, whereas in our cell system Dex concentrations as low as 
1 nM lead to a strong upregulation of MKP-1 and an effective deactivation of p38 MAPK. Interestingly, 
higher Dex concentrations (≥ 1,000 nM) do not lead to an induction of MKP-1, but reduce NF-κB 
activity. This suggests that the pathways Dex uses for the transduction of its anti-inflammatory 
properties depend on the applied concentration. It might be speculated that low (reflecting 
endogenous) glucocorticoid concentrations exert their anti-inflammatory properties rather via MKP-1 
than via NF-κB. Employing an inhibitor of the glucocorticoid receptor (GR), we proved an involvement 
of this receptor in the induction of MKP-1 by Dex. 
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4.2.4 MKP-1 is critical for the inhibition of p38 MAPK activity and E-selectin 
induction 
An involvement of MKP-1 in the action of glucocorticoids in endothelial cells has as yet been 
completely unknown. By using an MKP-1 antisense approach, we were able to show that Dex-induced 
MKP-1 plays a pivotal role both in the reduction of p38 MAPK and, importantly, E-selectin expression 
induced by TNF-α. It has to be stressed that we for the first time provide evidence that MKP-1 is a 
crucial mediator of the anti-inflammatory actions of glucocorticoids in the endothelium, since we 
discovered a functional impact of the upregulation of MKP-1 by Dex. 
4.2.5 The functional role of MKP-1 induction by Dex 
Besides its above discussed function as a mediator of profound cytoprotective effects (chapter 4.1.1), 
MKP-1 can also be regarded as an important transducer of anti-inflammatory actions. 
 
(i) MKP-1 was found to act as a negative regulator of the inflammatory response of macrophages, 
since MKP-1 is critically involved in the termination of LPS-induced signals responsible for the 
biosynthesis of the pro-inflammatory cytokines TNF-α and IL-6.143 In response to peptidoglycan, 
MKP-1-overexpressing macrophages were shown to produce substantially lower amounts of the pro-
inflammatory cytokines TNF-α and IL-1β.147 
 
(ii) In the context of resolution of inflammatory processes, MKP-1 participates in a negative feedback 
loop responsible for the limitation of inflammatory effects. A TNF-α-induced upregulation of MKP-1 
reduces p38 MAPK activity and E-selectin promoter activity evoked by TNF-α in the endothelium.148 
Moreover, in glomerular mesangial cells MKP-1 was found to limit the expression of the prominent 
pro-inflammatory mediator cyclooxygenase-2 (COX-2) induced by endothelin-1 (ET-1),149 a potent 
vasoconstrictor, which is thought to contribute to renal inflammatory diseases, such as 
glomerulonephritis. 
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(iii) Most importantly, MKP-1 has recently been assumed to be a novel regulatory mechanism for the 
action of glucocorticoids in different cell-types:74 in HeLa cells Dex was shown to destabilize the 
mRNA of COX-2 by inhibiting p38 MAPK function via an induction of MKP-1.139,150 Moreover, in 
rheumatoid arthritis synoviocytes MKP-1 was induced by Dex leading to a deactivation of different 
MAPK, which are known to be involved in the pathogenesis of rheumatoid arthritis.151 
 
It has to be noted that two studies by the group of Fogelman also deal with a pro-inflammatory role of 
MKP-1: they revealed a role for MKP-1 in oxidized low density lipoproteins (LDL)-induced signaling 
pathways leading to an expression of the pro-inflammatory cytokine monocyte chemoattractant 
protein-1 (MCP-1) in human aortic endothelial cells.152 Recently, they found that MKP-1 is expressed 
in atherosclerotic lesions of mice and that mice treated with the protein tyrosine phosphatase inhibitor 
sodium orthovanadate have smaller atherosclerotic lesions compared to the control group.153 Further 
studies are required in order to confirm these findings, since the simple appearance of MKP-1 in 
atherosclerotic lesions and the application of orthovanadate – an inhibitor of all tyrosine phosphatases 
– do not properly prove a critical involvement of MKP-1. Furthermore, it seems likely that MKP-1 is 
able to mediate conflicting effects in one single cell-type, since Chandrasekharan et al. reported that 
thrombin-induced MKP-1 differentially regulates thrombin-evoked effects: MKP-1 was found to 
increase platelet derived growth factor (PDGF), but to decrease VCAM-1 and E-selectin expression in 
thrombin-activated endothelial cells.154 MKP-1 seems to be able to mediate both pro- or anti-
inflammatory effects. Further investigations are necessary to elucidate the precise underlying 
mechanisms, which may depend on the experimental settings, the stimulus, or the activation status of 
the used cells. 
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5.1 MKP-1 and ANP 
The cardiovascular hormone atrial natriuretic peptide (ANP) protects endothelial cells against TNF-α-
induced activation by inducing MKP-1. In the present work we unraveled the underlying signaling 
pathway leading to an induction of MKP-1 by ANP (figure 59). An activation of the small Rho-GTPase 
Rac1 and, subsequently, of a Nox2-containing NAD(P)H oxidase were shown to initiate the signaling 
cascade. The resulting increase in the generation of superoxide, in turn, led to the activation of the 
JNK/AP-1 pathway, which was found to be crucial for the transcriptional upregulation of MKP-1 by 
ANP. Most importantly, we revealed that Rac1 and ROS take part in an ANP-activated transduction 
mechanism resulting in the increase of a cytoprotective mediator. 
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Figure 59: Signal transduction pathway of ANP leading to an induction of MKP.1 
 
5.2 MKP-1 and Dex 
Glucocorticoids are the most common group of drugs used for the treatment of inflammatory diseases. 
Their anti-inflammatory potential is generally ascribed to their ability to inhibit pro-inflammatory 
transcription factors, predominantly NF-κB. In the present study we discovered that dexamethasone 
(Dex), a synthetic glucocorticoid, is able to induce endothelial MKP-1 via the glucocorticoid receptor. 
This induction leads to a deactivation of p38 MAPK and, subsequently, to an inhibition of TNF-α-
activated endothelial E-selectin expression (figure 60). Interestingly, the upregulation of MKP-1 was 
achieved by Dex at very low concentrations (1-100 nM), at which an influence of Dex on the NF-κB 
pathway was excluded. Most importantly, we describe MKP-1 as a novel mediator of the anti-
inflammatory actions of glucocorticoids on endothelial cells. The induction of MKP-1 by Dex was for 
the first time linked to a functional effect in endothelial cells, i.e. the reduction of TNF-α-evoked E-
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selectin expression. In summary, we defined a new anti-inflammatory signal transduction mechanism 
for glucocorticoids in endothelial cells. This opens up new insights which may help to defeat two major 
problems in glucocorticoids therapy: resistance and side effects. 
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Figure 60: The glucocorticoid receptor (GR)-mediated induction of MKP-1 by dexamethasone (Dex) leads to an 
inhibition of the TNF-α-induced activation of p38 MAPK and, subsequently, E-selectin expression. 
 
 
5.3 MKP-1 as a central protective mediator of the endothelium 
In the recent years, the MAPK phosphatase MKP-1 emerged as an important cytoprotective mediator 
in different cell-types. The role of MKP-1 in the endothelium has as yet been widely unknown. In the 
present study we characterized the role of MKP-1 in mediating the anti-inflammatory and 
cytoprotective properties of the Atrial Natriuretic Peptide (ANP) and dexamethasone (figure 61). Pro-
inflammatory stimuli, such as TNF-α, lead to an activation of endothelial cells, i.e. the expression of 
different adhesion molecules (e.g. E-selectin), cytokines (MCP-1), or the reorganization of cytoskeletal 
elements resulting in stress fiber formation or increase of permeability. p38 MAPK is crucially involved 
in the signaling leading to the TNF-α induced deterioration of endothelial functionality. MKP-1, induced 
by ANP and Dex, exerts its effects by inhibiting p38 MAPK activity. The findings of the present study 
provide a further insight into both the functions and the mechanisms of induction of MKP-1. This 
highlights the potential of this phosphatase as a useful and valuable drug target. 
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Figure 61: MKP-1 as a central protective mediator of the endothelium. 
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7.1 Abbreviations 
A  Ampere 
ANP  atrial natriuretic peptide 
AP-1  activator protein-1 
BNP  brain natriuretic peptide 
°C  degrees Celsius 
CAM  cell adhesion molecule 
cGMP  cyclic guanosin-5’-monophosphate 
cpm  counts per minute 
CNP  C-type natriuretic peptide 
Co  control 
Dex  dexamethasone 
DNA  desoxyribonucleic acid 
EC  endothelial cell 
EMSA  electrophoretic mobility shift assay 
ERK  extracellular-regulated kinase 
g  gram 
GC  glucocorticoid 
GDP  guanosine-5’-diphosphate 
GR  glucocorticoid receptor 
GTP  guanosine-5’-triphosphate 
h  hour 
HMEC  human microvascular endothelial cell 
HUVEC human umbilical vein endothelial cell 
ICAM-1  intercellular adhesion molecule-1 
JNK  c-Jun N-terminal kinase 
l  liter 
m  meter 
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m  milli (10-3) 
M  molar 
µ  micro (10-6) 
min  minute 
MAPK  mitogen-activated protein kinase 
MCP-1  monocyte chemoattractant protein-1 
MKP  mitogen-activated protein kinase phosphatase 
mRNA  messenger ribonucleic acid 
n  nano (10-9) 
NADPH nicotinamide dinucleotide phosphate 
NF-κB  nuclear factor-κB 
NO  nitric oxide 
Nox  NAD(P)H oxidase 
NP  natriuretic peptide 
NPR  natriuretic peptide receptor 
PCR  polymerase chain reaction 
PKC  protein kinase C 
PKG  protein kinase G (cGMP-dependent protein kinase) 
RNA  ribonucleic acid 
ROS  reactive oxygen species 
rpm  rotations per minute 
s  second 
SEM  standard error of the mean value 
SOD  superoxide dismutase 
TNF-α  tumor necrosis factor-α 
VCAM-1 vascular cell adhesion molecule-1 
VSMC  vascular smooth muscle cell 
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7.2 Alphabetical list of companies 
Alexis      Grünberg, Germany 
AGFA      Cologne, Germany 
Amersham     Freiburg, Germany 
Bachem     Heidelberg, Germany 
BD Biosciences    Heidelberg, Germany 
Biochrom     Berlin, Germany 
biomers.net     Ulm, Germany 
Biomol      Hamburg, Germany 
Bio-Rad     Munich, Germany 
BioWhittaker     Rockland, USA 
Biozol      Eching, Germany 
Calbiochem     Schwalbach, Germany 
Cambrex     Verviers, Belgum 
Canberra-Packard    Dreieich, Germany 
Cell Signaling/New England Biolabs  Frankfurt/Main, Germany 
Chiron Diagnostics    Fernwald, Germany 
DakoCytomation    Hamburg, Germany 
Dianova     Hamburg, Germany 
Fuji      Düsseldorf, Germany 
Gibco/Invitrogen    Karlsruhe, Germany 
Hellige      Erlangen, Germany 
Interdim     Montluçon, France 
Kodak      Rochester, USA 
Leinco/Biotrend     Cologne, Germany 
Merck      Darmstadt, Germany 
Millipore     Schwalbach, Germany 
Minerva Biolabs    Berlin, Germany 
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Molecular Probes/Invitrogen   Karlsruhe, Germany 
MWG      Ebersberg, Germany 
Olympus Optical    Hamburg, Germany 
Owl Separation Systems   Portsmouth, USA 
PAN Biotech     Aidenbach, Germany 
PerkinElmer     Überlingen, Germany 
Polyplus Transfection/Biomol   Hamburg, Germany 
Promega     Heidelberg, Germany 
Promocell     Heidelberg, Germany 
Qiagen      Hilden, Germany 
Roche      Mannheim, Germany 
Roth      Karlsruhe, Germany 
Santa Cruz     Heidelberg, Germany 
Saxon      Hannover, Germany 
Siemens     Erlangen, Germany 
Sigma-Aldrich     Taufkirchen, Germany 
SIMS Portex     Kent, UK 
Stratagene     La Jolla, USA 
TILL Photonics     Martinsried, Germany 
TPP      Trasadingen, Switzerland 
Upstate/Biomol     Hamburg, Germany 
USB      Cleveland, USA 
Zeiss      Oberkochen, Germany 
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7.3.3 Oral presentations 
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7.3.4 Poster presentations 
Fürst R, Zahler S, Vollmar AM, Kiemer AK. MKP-1 mediates anti-inflammatory effects of 
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7.4 Curriculum vitae 
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Name:    Robert Fürst 
Geburtstag und -ort:  1. März 1975, Temeschburg 
Staatsangehörigkeit:  deutsch 
Famillienstand:   ledig 
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